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                                       ORAL DRUG DELIVERY
1 
Oral drug delivery is the most desirable and preferred method of administering therapeutic 
agents for systemic effects. In addition oral medication is the first avenue investigated in the 
discovery and development of new drug entities and pharmaceutical formulations mainly 
because of patient acceptance, convenience in administration and cost effective 
manufacturing process. For many drug substances, conventional immediate release 
formulations provide clinically effective therapy while maintaining the required balance of 
pharmacokinetic and pharmacodynamic profiles with an acceptable level of safety to the 
patient. 
Based on desired therapeutic objectives, oral drug delivery systems may be assorted into 
three categories: 
 Immediate- release preparations 
 Controlled- release preparations 
 Targeted- release preparations 
Immediate release preparations 
These preparations are primarily intended to achieve faster onset of action for drugs such as 
analgesics, antipyretics, and coronary vasodilators. Other advantages include enhanced oral 
bioavailability through transmucosal drug delivery and pregastric absorption, convenience in 
administration to dysphasic patients, especially the elderly and bedridden and new business 
opportunities. 
Controlled release preparations 
The currently employed CR technologies for oral drug delivery are diffusion- controlled 
systems; solvent activated systems and chemically controlled systems. Diffusion controlled 
systems include monolithic and reservoir devices in which diffusion of the drug is the rate 
limiting step through a polymer matrix or a polymeric membrane respectively. Solvent 
activated systems may be either osmotically controlled or controlled by polymer swelling. 
Chemically controlled systems release drugs via polymeric degradation (surface or bulk 
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matrix erosion) or cleavage of drug from polymer chain. It is worth mentioning here that so 
called programmed release (tailored release) profile of a final CR product is rarely the 
outcome of a single pharmaceutical principle. Depending upon physicochemical properties of 
the drug in question and desired therapeutic objectives different formulations and CR 
principles may be proportionally combined within the same dosage form. This task appears to 
be simpler when realized in terms of appropriate selection of polymers and excipients that 
incorporate different principles. 
Targeted release preparations
 
Site specific oral drug delivery requires special placement of drug delivery device at a desired 
site within the GI tract. Although it is virtually possible to localize a device within each part 
of GI tract, the attainment of site specific delivery in the oral cavity and the rectum is 
relatively easier than in the stomach and the small and large intestines. The later requires 
consideration of both longitudinal and transverse aspects of GI constraints. Some of the 
potential CR and site specific DDSs will be described. 
                                                        TABLETS
2 
Tablets are solid dosage forms consisting of one or more active ingredient were compressed 
into various shapes and sizes. Tablet is the most popular among all dosage forms existing 
today because of its convenience of self-administration, compactness and easy 
manufacturing; however in many cases immediate onset of action is required than 
conventional therapy. To overcome these drawbacks, immediate release pharmaceutical 
dosage form has emerged as alternative oral dosage forms. The immediate release tablets are 
prepared by using super disintigrants like Cross linked Carboxymethylcellulose 
(Croscarmellose), Sodium starch glycolate (Primogel, Explotab), Polyvinylpyrrolidone 
(Polyplasdone) etc. which provide instantaneous disintegration of tablet after administration. 
Advantages of tablets 
 They provide an accurately measured dose and low content variability of the unit 
dose. 
 They are of low manufacturing cost. 
 They are easy to package and ship. 
18 
 
 They are simple to identify. 
 Manufacturing processes and techniques provide tablets certain special release 
products such as enteric and delayed release products 
Disadvantages of tablets 
 Some drugs may cause local irritation effect harmful to gastro intestinal mucosa. 
 Some drugs resist compression into dense compacts, owing to their amorphous 
nature or flocculent, low-density character. 
 Bitter tasting drugs, drug with obnoxious odor or drugs that are sensitive to oxygen 
or atmospheric moisture may require encapsulation / entrapment prior to 
compression. 
TYPES OF TABLETS 
Oral tablets for ingestion:  
These tablets are meant to be swallowed intact along with a sufficient quantity of potable 
water. Exception is chewable tablet. Over 90% of the tablets manufactured today are ingested 
orally. This shows that this class of formulation is the most popular worldwide and the major 
attention of the researcher is towards this direction. 
 Standard compressed tablets 
 Multiple compressed tablets 
 Compression coated tablet 
 Layered tablet 
 Inlay tablet 
 Modified Release tablet 
 Delayed action tablet 
 Targeted tablet 
 Floating tablet 
 Colon targeting tablet 
 Chewable tablet 
 Dispersible tablet 
 Immediate release tablet 
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Tablets used in the oral cavity  
These tablets are aimed release API in oral cavity or to provide local action in this region. 
The tablets under this category avoids first-pass metabolism, decomposition in gastric 
environment, nauseatic sensations and gives rapid onset of action. The tablets formulated for 
this region are designed to fit in proper region of oral cavity. 
 Lozenges and troches 
 Sublingual tablet 
 Buccal tablet 
 Dental cones 
 Mouth dissolved tablet 
Tablets administered by other routes  
These tablets are administered by other route except for the oral cavity and so the drugs are 
avoided from passing through gastro intestinal tract. These tablets may be inserted into other 
body cavities or directly placed below the skin to be absorbed into systemic circulation from 
the site of application. 
 Vaginal tablet 
 Implants 
Tablets used to prepare solution  
The tablets under this category are required to be dissolved first in water or other solvents 
before administration or application. This solution may be for ingestion or parenteral 
application or for topical use depending upon type of medicament used. 
 Effervescent tablet 
 Hypodermic tablet 
 Soluble tablet 
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                                                    ADDITIVES
3 
DILUENTS: 
Diluents are substances to increase bulk and convert in the compressible form, when drug 
material is potent or inadequate to provide a suitable shape and size to tablet. 
A tablet diluent must be compatible, inert, economic, easily available and organoleptically 
acceptable, should not affect the bioavailability of a drug adversely. 
Examples of tablet diluents include dibasic calcium phosphate, calcium sulphate, lactose, 
lactose anhydrous, lactose spray dried, mannitol, sorbitol, sucrose, dextrose etc. 
Examples of directly compressible diluents include Sta-Rx-1500, Emdex (contains dextrose 
90 to 92%, a maltose 3 to 5%), Celutab (dextrose & maltose), Avicel (Microcrystalline 
cellulose), Di-C (Dicalcium phosphate dihydrate), Cab-O-Sil (Colloidal silica). 
BINDERS and ADHESIVE: 
These materials are used in dry or liquid form to reduce the amorphous nature of substance 
and convert into compressible form (wet granulation). Example include acacia, tragacanth, 
gelatin, alginates, methylcellulose, hydroxypropyl- methylcellulose, hydroxypropylcellulose, 
PVP, Starch, sorbiol, ethylcellulose, pregelatinized starch, glucose, iris moss, ghatti gum, 
arabogalactan, waxes, etc. 
DISINTEGRENT: 
Most of the tablets contain disintegrating agent. Disintegrating agents facilitate the 
disintegration of the tablet in small particles in the gastrointestinal tract. Breaking of tablet' 
based on the swell ability, adsorption of water or chemical reaction.  
Examples include soluble starch, pre-gelatinized starch (PGS), veegum HV, bentonite, 
microcrystalline cellulose, sodium carboxy methylcellulose, PVP, guar gum, Isapgul, 
primogel, explotab, aerosil, natural spon citrus pulp, Alginic acid and alginates, Ion exchange 
resin, magnesium aluminium silicat modified corn starch, sodium dodecyl sulphate, sodium 
starch glycollate, etc. 
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SUPER DISINTEGRENTS:  
In recent years, several newer agents have been developed known as “Superdisintegrants”. 
These newer substances are more effective at lower concentrations with greater disintegrating 
efficiency and mechanical strength. On contact with water the superdisintegrants swell, 
hydrate, change volume or form and produce a disruptive change in the tablet. Effective 
superdisintegrants provide improved compressibility, compatibility and have no negative 
impact on the mechanical strength of formulations containing high-dose drugs. Super 
disintegrants offer significant improvements over starch. But hygroscopicity may be a 
problem in some formulations.  
As days pass, demand for faster disintegrating formulation is increased. So, pharmacist needs 
to formulate better disintegrants i.e. Superdisintegrants which are effective at low 
concentration and have greater disintegrating efficiency and they are more effective 
intragranularly. And these superdisintegrants act by swelling and due to swelling pressure 
exerted in the outer direction or radial direction, it causes tablet to burst or the accelerated 
absorption of water leading to an enormous increase in the volume of granules to promote 
disintegration. Three major groups of compounds have been developed which swell to many 
times their original size when placed in water while producing minimal viscosity effects. 
Different  types of commonly used superdisintegrants are 
 Modified Starches- Sodium Carboxymethyl Starch (Sodium Starch Glycolate) 
 Cross-linked Polyvinylpyrrolidone (Crospovidone) 
 Modified Cellulose (Croscarmellose sodium) 
 Soy polysaccharide 
 Cross-linked alginic acid 
 Gellan gum  
 Xanthan gum 
 Calcium Silicate 
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GLIDANTS:  
Glidants act as a flow promoter and reduce the friction between particles. It improves the 
flow properties of granules or powder through hopper to die. It is not deformed compression 
pressure of the tablet machine. Examples include talc, starch, magnesium stearate, calcium 
stearate, boric acid, sugar, lycopodium and sodium chloride. 
LUBRICANTS: 
Lubricants reduce inter-particular friction. It improves the ejection of tablet from die wall and 
reduces the sticking problems and smooth tablets are produced. Examples include Talc, 
magnesium stearate, calcium stearate, stearic acid, polyethylene glycols, starch derivative 
ANTI-ADHESIVES or ANTI-STICKING AGENTS: 
These materials are used to reduce the adhesion of the tablet surface to dies and punches 
during the compression of tablets. The pressure of the machine deforms these materials. It 
reduces sticking, picking and chipping problems. Examples include paraffin, stearic acid, 
cocoa butter, soaps, starch derivatives. 
COLORING AGENTS: 
Colors are selected from 'permitted' list and are added to promote elegance and also to mask 
differences in color or speckling when either the drug or an additive is off white. 
Pastel shades are commonly used as these shades help in achieving uniform color 
distribution. Coloring materials or dyes are used in tablet formulation mainly for three 
purposes; disguising of off color drugs, product identification and production of more elegant 
products. Colors may be added either to the vehicle used for granulation or to the mixture of 
powders prior to granulation. 
The first approach is known to give better results provided migration of dye to the top of 
granules along with solvent during drying does not occur. When wet granulation is not to be 
employed, lake dyes (dyes adsorbed on alumina or aluminium hydroxide) are recommended. 
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Fading of the color on standing and exposure to light leading to mottling of tablets is the 
common problem with dyes. Examples include water soluble dyes and many other FD&C 
approved colors or dyes. 
FLAVORING AGENTS:  
These substances are not necessary for the formulation of compressed tablets. The proportion 
of flavors should generally be limited to 0.5% because excessive amounts may interfere with 
the free flow or cohesion of the granules. Special tablets require flavoring agents such as 
chewable tablet, lozenges, etc. Examples include flavoring oils like cinnamon, coriander, and 
caraway etc. 
SWEETENERS:  
Chewable tablets have sweetening agents because such tablets remain in the mouth and are 
not swallowed. Examples include saccharin sodium, aspartame, sugar, etc 
                                    MANUFACTURING METHOD
4 
Pharmaceutical products are processed all over the world using the direct compressing, wet 
granulation or dry granulation methods. Method is chosen depend on the ingredients 
individual characteristics like flow property, compressibility. Choosing a method requires 
thorough investigation of each ingredient in the formula, the combination of ingredients, and 
how they work with each other. Then the proper granulation process can be applied.  
DIRECT COMPRESSION 
 
Direct compression name implies compressing tablets directly from powdered materials 
without modifying the physical nature of the materials itself. Direct compression is generally 
done for the crystalline materials having good physical properties required for formation of 
good tablets. Main advantage of direct compression is it saves time when compared to other 
methods of compression like wet granulation.  
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Main Steps Involved in the direct compression method 
Milling of drugs and excipients 
 
Mixing of excipients 
 
Tablet compression 
FACTORS TO BE CONSIDERED FOR DIRECTLY COMPRESSIBLE EXCIPIENTS 
FLOWABILITY 
Press speed requires powders to be very fluid, a property commonly referred to as product 
flowability. Good flow characteristics are necessary because the mechanical action of the 
tablet press requires a volume of fill and this volume of fill represents the actual tablet 
weight. Thus the powders in the formula must possess a consistent particle-size distribution 
and density to attain proper flow and achieve volume of fill. 
COMPRESSIBILITY 
Compressing a tablet of different powders that have varying physical characteristics can be 
difficult. If the formula has some of both characteristics large particles with high moisture 
content and small dry particles then the tablet may or may not compress well and probably 
will have difficulty holding together.  
Directly compressible materials are pre-processed or are found naturally in the granular state. 
The reduced number of processing steps required by directly compressible materials allows 
for less equipment and shorter process times in comparison with wet- or dry-granulation 
processes. 
WET GRANULATION
 
Most widely used and most general method of tablet preparation is by wet granulation 
method. Wet granulation forms the granules by binding the powders together with an 
adhesion instead of by compaction. The wet granulation technique is done by adding a solute, 
suspension or slurry containing binder this can be aqueous or non-aqueous which is added to 
the dry mix powder. In general the mass should be moist rather than wet or paste merely. The 
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surface tension forces and capillary pressure are primarily responsible for initial granules 
formation. The main advantage is it meets the all requirements for tablet formation and main 
disadvantage is it requires many steps in process, which is time consuming. 
                 Main Steps Involved in the Wet granulation method 
                                                  Sifting of Drugs and Excipients 
                                                      Mixing of Milled Powders 
                                                 Preparation of Binder Solution 
                       Mixing of Binder Solution with powder mixer to form wet mass 
                                                   Drying of Moist Granules 
                              Screening Dry Granules, Lubricant and Disintegrants 
                              Mixing of Screened Granules with Disintegrants and lubricant 
                                                            Tablet compression 
DRY GRANULATION 
The dry granulation process is used to form granules without using a liquid solution. This 
type of process is recommended for products, which are sensitive to moisture and heat. 
Forming granules without moisture requires compacting and densifying the powders. Dry 
granulation can be done on a tablet press using slugging tooling. On large-scale roller 
compactor commonly referred to as a chilsonator. The compacted mass is called slugs and the 
process is known as slugging. The slugs are then screened or milled to produce a granular 
form of tablet materials, which have the good flow properties than original powder mixture.  
The main advantage of dry granulation is it requires less equipment and eliminates the 
addition of moisture and the application of heat, as found in wet massing and drying steps of 
the wet granulation method 
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                        Main Steps Involved in the Dry granulation method 
                                               Milling of Drugs and Excipients 
                                                  Mixing of Milled Powders 
                                       Compression into large, hard tablets called slugs 
                                                        Screening of slugs 
                                     Mixing with lubricant and disintegrating agent 
                                                        Tablet Compression. 
                                Gastroretentive drug delivery systems 
5-14.
  
Controlled release (CR) dosage forms have been extensively used to improve therapy with 
several important drugs. However, the development processes are faced with several 
physiological difficulties such as the inability to restrain and localize the system within the 
desired region of the gastrointestinal tract and the highly variable nature of the gastric 
emptying process. This variability may lead to unpredictable bioavailability and time to 
achieve peak plasma level. On the other hand, incorporation of the drug in a controlled 
release gastroretentive forms (CR-GRDF) which can remain in the gastric region for several 
hours would significantly prolong the gastric residence time of drugs and improve 
bioavailability, reduce drug waste, and enhance the solubility of drugs that are less soluble in 
high pH environment. Gastroretention would also facilitate local drug delivery to the stomach 
and proximal small intestine. Thus, gastroretention could help to provide greater availability 
of new products and consequently improved therapeutic activity and substantial benefits to 
patients 
BASIC GASTROINTESTINAL TRACT PHYSIOLOGY 
Stomach has mainly 4 main regions: The cardia, fundus, body and pylorus. The cardia 
surrounds the superior opening of the stomach. Pylorus has 2 main parts:- pyloric antrum 
which connects body of the stomach and the pyloric canal leads to duodenum. Body is the 
large central portion of the stomach which is inferior to the fundus. Body acts as reservoir for 
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                                     Fig 1: Anatomy of stomach 
 
undigested material, whereas the antrum is the main site for mixing motions and acts as a 
pump for gastric emptying by propelling actions.  
Gastric emptying occurs during fasting as well as fed states. The pattern of motility is 
however distinct in the 2 states.The fasted state is associated with some cyclic contractile 
events commonly known as migrating myoelectric complex (MMC) which cycle both 
through stomach and intestine every 2 to 3hours. Apparently there are four consecutive 
phases of activity in the MMC. 
Phase-I (basal phase): It is a quiescent period lasting from 30 to 60min with no contractions.  
Phase-II (preburst phase): It consists of intermittent contractions that gradually increase in 
intensity as the phase progresses, and lasts about 20-40min. Gastric discharge of fluid and 
very small particles begins later in this phase.  
Phase-III (burst phase): This is a short period of intense distal and proximal gastric 
contractions (4-5 contractions per minute) lasting about 10-20minutes. These contractions 
also known as “house keeper waves” sweep gastric contents down the small intestine.  
Phase-IV: This is a short transitory period of about 0-5minutes, and the contractions dissipate 
between the last part of phase-III and phase-I 
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          Fig 2: Schematic representation of inter digestive motility pattern 
 
. 
 
The different phases originating in the foregut continue to the terminal ileum, another begins 
in the stomach and duodenum. Liquid components easily pass through the partially 
constricted sphincter. On the contrary, the large undigested materials are retained by an 
“antral-seieving” process and are retropulsed into the body of stomach and remain in the fed 
state. In the fed state, gastric contractions move the contents towards the antrum and the 
pyloric sphincter.  
After the ingestion of a mixed meal, the pattern of contractions changes from fasted to that of 
fed state. This is also known as digestive motility pattern and comprises continuous 
contractions as in the phase-II of fasted state. These contractions results in reducing the size 
of food particles (to less than 1mm) which are propelled towards the pylorus in a suspension 
form. During the fed, state onset of MMC is delayed resulting in slow down of gastric 
emptying rate.  
APPROACHES TO PROLONG GASTRIC RESIDENCE TIME 
The need for gastroretentive dosage forms (GRDFs) has led to extensive efforts in both 
academia and industry towards the development of such drug delivery systems.  
These efforts resulted in GRDFs that were designed in large part, based on the following 
approaches. 
29 
 
1. Floating drug delivery systems  
2. High density systems  
3. Bioadhesion to stomach mucosa  
4. Slowed motility of gastrointestinal tract by concomitant administration of                                                                                                                                                                                                                                      
drugs or pharmaceutical excipients  
5. Expansion by swelling or unfolding to a large size which limits emptying of dosage form 
through the pyloric sphincter  
FLOATING DRUG DELIVERY SYSTEMS 
Floating drug delivery systems have a bulk density less than gastric fluids and so remain 
buoyant in the stomach without affecting the gastric emptying rate for a prolonged period of 
time while the system is floating on the gastric contents the drug is released slowly at the 
desired rate from the system. This results in increased GRT and better control of fluctuations 
in plasma drug concentration. 
 
                               Fig 3: Mechanism of Floating System 
 
 
1. SINGLE UNIT FLOATING DOSAGE FORM  
 a. Non-effervescent systems: The most commonly used excipients in non-effervescent 
FDDS are gel forming or highly swellable cellulose type hydrocolloids, polysaccharides and 
matrix forming polymers such as polycarbonate, polyacrylate, polymethacrylate and 
polystyrene., which swells in contact with gastric fluids after oral administration and 
maintains a relatve integrity of shape, bulk density of less than unity. The air entrapped by the 
swollen polymer confers buoyancy to these dosage forms.   
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 i. Colloidal gel barrier system: This system incorporates a high level (20-75%w/w) of one 
or more gel-forming, highly swellable, cellulose type hydrocolloids (e.g. Hydroxy ethyl 
cellulose, hydroxy propyl cellulose, hydroxy propyl methyl cellulose , sodium carboxymethyl 
cellulose) polysaccharides and matrix forming polymers such as polycarbophil, polyacrylates 
and polystyrene, incorporated either in tablets or in capsules. When coming in contact with 
gastric fluid, the hydrocolloid in the system hydrates and form colloidal gel barrier around its 
surface. This gel-barrier control the rate of fluid penetration into the device and consequent 
release of the drug. As the exterior surface of the dosage form goes into the solution, the gel 
layer is maintained by the adjacent hydrocolloid layer becoming hydrated. The air trapped in 
by the swollen polymer maintains a density less than unity and confers buoyancy to these 
dosage forms.   
The HBS must comply with 3 major criteria:  
1) It must have sufficient structure to form a cohesive gel barrier  
2) It must maintain an overall specific density lower than that of gastric contents  
3) It should dissolve slowly enough to serve as a reservoir for the delivery system.  
A bilayer tablet can also be prepared to contain one immediate-release and sustained release 
layer. Immediate-release layer delivers the initial dose, whereas SR layer absorbs gastric fluid 
and forms a colloidal gel barrier on its surface. This results in a system with bulk density 
lesser than that of the gastric fluid, and allows it to remain buoyant in stomach for an 
extended period of time.  
Fig 4: Working principle of hydro dynamically balanced systems 
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ii. Microporous compartment system: This technology is based on the encapsulation of a 
drug reservoir inside a microporous compartment with apertures along its top and bottom 
walls. The peripheral wall of the drug reservoir compartment is completely sealed to prevent 
any direct contact of gastric mucosal surface with the un-dissolved drug. In stomach, the 
floatation chamber containing entrapped air causes the delivery system to float over the 
apertures, dissolves the drug and carries the dissolved drug for continuous transport across 
the intestine for absorption.   
 b. Effervescent systems: A drug delivery system can be made to float in the stomach by 
incorporating a floating chamber, which may be filled with vaccum, air or inert gas. The gas 
in the floating chamber can be introduced either by the volatilization of an organic solvent or 
by the effervescent reaction between organic acids and bicarbonate salts.   
 i. Volatile liquid containing systems: The GRT of a drug delivery system can be sustained 
by incorporating an inflatable chamber which contains a liquid e.g. ether, cyclopentane that 
gasifies at body temperature to cause the inflatation of the chamber in the stomach. These 
devices are osmotically controlled floating systems containing a hollow deformable unit that 
can convert from a collapsed to an expanded position and returns to collapsed position after 
an extended period. The deformable system consists of two chambers separated by an 
impermeable, pressure-responsive, movable bladder. The first chamber contains the volatile 
liquid. The device inflates and the drug is continuously released from the reservoir into the 
gastric fluid. The device may also consists of a bioerodible plug made up of PVA, 
polyethylene etc. that gradually dissolves causing the inflatable chamber to release gas and 
collapse after a predetermined time to permit spontaneous ejection of the inflatable system 
from the stomach  
Fig 5: Intra gastric floating gastrointestinal drug delivery device 
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ii. Gas-generating systems : These buoyant systems use matrices prepared with swellable 
polymers like HPMC, polysaccharides like chitosan, effervescent components like sodium 
bicarbonate, citric acid, tartaric acid, Di-sodium glycine carbonate, citroglycine etc. The 
optimal stoichiometric ratio of citric acid and sodium bicarbonate for gas generation is 
reported to be 0.76:1. Effervescent reaction between bicarbonate salts and citric acid/tartaric 
acid liberates CO2,which gets entrapped in the gellified hydrocolloid layer of the system, 
thus decreasing its specific gravity and making it to float over chyme. These tablets may be 
either single layered wherein the carbondioxide generating components are intimately mixed 
within the tablet matrix, or they may be bilayered in which the gas generating components are 
compressed in hydrocolloid containing layer and the drug in other layer formulated for a SR 
effect. 
 
Fig 6: Schematic representation of floating pill, (a) The penetration of water into 
effervescent layer leads to a Co2 generation and makes the system to float. (b) 
A)Penetration of water into the device; B) generation of carbon dioxide and floating; C) 
dissolution of the drug. Where, a) Conventional sustained release core; b) effervescent layer; 
c) swellable layer; d) expanded swellable membrane layer; e) water surface in the beaker  
 
.  
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2. MULTIPLE UNIT FLOATING DOSAGE FORM  
 a. Non-effervescent system  
 i. Alginate beads:
 
Spherical beads of approximately 2.5mm in diameter can be prepared by 
dropping a sodium alginate solution into aqueous solution of calcium alginate. The beads are 
then separated, snap frozen in liquid nitrogen and freeze-dried at -400C for 24 hours, leading 
to the formation of a porous system, which can maintain a floating force for 12 hours.  
 ii. Hollow microspheres:
 
Hollow microspheres are considered as one of the most promising 
buoyant systems as they possess the unique advantages of multiple unit systems as well as 
better floating properties, because of the central hollow space inside the microsphere. The 
general techniques involved in their preparation include simple solvent evaporation and 
solvent diffusion and evaporation. Polymers such as polycarbonate, eudragit S and cellulose 
acetate are used in the preparation of hollow microspheres and the drug release can be 
modified by optimizing the amount of polymer-plasticizer ratio. Hollow microspheres floated 
with drug in their outer polymer shelf can also be prepared by a novel emulsion solvent-
diffusion method. The ethanol/dichloromethane solution of the drug and an enteric acrylic 
polymer was poured into an agitated solution of poly vinyl alcohol that was thermally 
controlled at 400C. The gas phase is generated in the dispersed polymer droplet by the 
evaporation of dichloromethane formed an internal cavity in the microsphere of the polymer 
with drug. The micro balloon floated continuously over the surface of an acidic dissolution 
media containing surfactant for more than 12 hours.  
 b. Gas-generating systems: 
 
Multi unit types of floating pills, which generate CO2 have 
also been developed. The system consists of a SR pill as seed, surrounded by double layers. 
The inner layer is an effervescent layer containing sodium bicarbonate and tartaric acid. 
When the system is immersed in buffer solution at 37
0
C swollen pills, like balloons are 
formed having density less than 1g/ml. This occurs due to CO2 neutralization of the inner 
effervescent layer with the diffusion of water through the outer swellable membrane layer. 
These kinds of systems float completely within 10min and remain floating over extended 
periods of 5-6 hours.   
 c. Ion-exchange resin system: The system consisted of resin beads, which were loaded with 
the bicarbonate and a negatively charged drug that was bound to the resin. The resultant 
beads were then encapsulated in a semipermeable membrane to overcome rapid loss of CO2. 
Upon arrival in the acidic environment of stomach, an exchange of chloride and bicarbonate 
ions took place. As a result of this reaction, carbon dioxide was released and trapped in the 
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membrane, thereby carrying beads towards the top of gastric contents and producing a 
floating layer of resin beads.   
Bio/Mucoadhesive systems: 
Bioadhesive drug delivery systems (BDDS) are useful as a delivery device within the lumen 
to enhance drug absorption in a site-specific manner. This approach involves the use of 
bioadhesive polymers, which can adhere to the epithelial surface in the stomach. Gastric 
mucoadhesion does not tend to be strong enough to impart the dosage forms the ability to 
resist the strong propulsion forces of the stomach wall. The continuous production of mucous 
that is lost through peristalitic contractions and the dilution of the stomach contents also seem 
to limit the potential of mucoadhesion as a gastroretentive force. Some of the most promising 
excipients that have been used commonly in these systems include polycarbophil, carbopol, 
lectins, chitosan and gliadin etc. The adhesion of the polymers with the mucous membrane 
may be mediated by hydration, bonding or receptor mediated.  
                                Fig 7:  Bio- Adhesion of microspheres. 
 
 
Swelling systems: 
Swelling systems are also referred to as plug type systems. The presence of polymers in the 
systems promotes their swelling to a size that prevents their passage through pyloric sphincter 
resulting in prolonged GRT. However, a balance between the rate and extent of swelling and 
the rate of erosion of the polymer is crucial to achieve optimum benefits and to avoid 
unwanted side effect 
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High density system:
 
This approach involves formulation of dosage forms with the density that must exceed 
density of normal stomach content (1.004g/cm3). These formulations are prepared by coating 
drug on a heavy core or mixed with heavy inert materials such as iron powder, zinc oxide, 
titanium dioxide or barium sulphate. These resultant pellets can be coated with diffusion 
controlled membrane. These systems with a density of about 3g/cm3 are retained in the rugae 
of the stomach and are capable of withstanding its peristalitic movements. 2.6-2.8g/cm3 acts 
as a threshold density after which such systems can be retained in the lower part of the 
stomach.  
 
                   Fig 8: High density and Low density systems 
 
 
 
Expansive gastroretentive dosage form 
This is a class of gastroretentive systems capable of expanding in stomach. The expanded 
structure is trapped in stomach for prolonged period leading to sustained drug release and 
subsequent controlled absorption in stomach and intestine. These systems are administered 
perorally in the form of capsule bearing the dosage form in folded and compact 
configuration. When exposed to gastric environment capsule shell breaks and the dosage 
form attains its expanded structure, which is retained in stomach for longer time. The serous 
drawback of this system is clogging of pylorus end of stomach.  
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Raft forming systems: 
Raft forming systems have received much attention for the delivery of antacids and drug 
delivery for gastrointestinal infections a 
nd other disorders. The mechanism involved in the raft formation includes the formation of a 
viscous cohesive gel in contact with gastric fluids, wherein each portion of the liquid swells 
forming a continuous layer called a raft. This raft floats on gastric fluids because of the low 
bulk density created by the formation of CO2. Usually, the system contains a gel forming 
agents and alkaline bicarbonates or carbonates responsible for the formation of CO2 to make 
the system less dense and able to float on the gastric fluids. This floating rafts impedes the 
reflux of acids and food by acting as a physical barrier. The raft has a pH value higher than 
that of the stomach contents so that in the event of gastric reflux, the wall of the esophagus is 
not subjected to irritation by Hcl. 
 
Fig 9: Schematic Illustration of the barrier formed by raft forming system 
   
 
SUITABLE CANDIDATE FOR GASTRIC RETENTION 
In general, appropriate candidates for CR-GRDF are molecules that have poor colonic 
absorption but are characterized by better absorption properties at the upper parts of the GIT: 
 
 Narrow absorption window in GI tract, e.g. Riboflavin and levodopa  
 Primarily absorbed from stomach and upper part of GI tract e.g. calcium  
           supplements, chlorodiazepoxide and cinnarazine.  
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 Drugs that act locally in the stomach e.g. antacids and misoprostol  
 Drugs that degrade in the colon e.g. ranitidine Hcl and metronidazole  
 Drugs that disturb normal colonic bacteria, e.g. amoxicillin trihydrate  
FACTORS AFFECTING FLOATING DRUG DELIVERY SYSTEM
 
 1. Density of dosage form: Dosage forms having a density lower than that of gastric fluid 
experience floating behavior and hence gastric retention. Density <1.0g/cm3 is required to 
exhibit floating property.   
 2. Size of dosage form: The size of the dosage form is another factor that influences gastric 
retention .The mean gastric residence times of non-floating dosage forms are highly variable 
and greatly dependent on their size, which may be small, medium and large units. In fed 
conditions, the smaller units get emptied from the stomach during the digestive phase and the 
larger units during the house keeping waves. In most cases, the larger the size of the dosage 
form the greater will be the gastric retention time because the larger size would not allow the 
dosage form to quickly pass through the pyloric sphincter into the intestine. Dosage form 
units with a diameter more than 7.5mm are reported to increase GRT compared with those 
with diameter of 9.9mm.   
3. Food intake and nature of food: Food intake, the nature of the food, caloric content and 
frequency of feeding has a profound effect on the gastric retention of dosage forms. The 
presence or absence of food in the stomach influences the GRT of the dosage forms. Usually, 
the presence of food increases the GRT of the dosage form and increases drug absorption by 
allowing it to stay at the absorption site for a longer time. Usually fats tend to form an oily 
layer on the other gastric contents. As such, fatty substances are emptied later than other. 
Also, increased acidity and osmolality slow down gastric emptying.   
4. Stress: stress appears to cause an increase in gastric emptying rate, while depression slows 
it down.   
5. Sex: women and elderly have a slower gastric emptying rate than men and young people 
respectively.   
6. Posture: In a comparative study in humans by Gansbeke et al; the floating and non-
floating systems behaved differently. In the upright position, the floating systems floated to 
the top of the gastric contents and remained for a longer time, showing prolonged GRT. But 
the non-floating units settled to the lower part of the stomach and underwent faster emptying 
as a result of peristaltic contractions and the floating units remained away from the pylorus. 
However, in supine position, the floating units are emptied faster than non-floating units of 
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similar size. A study by Mojaverian et al showed that effect of posture on GRT found no 
significant difference in mean GRT for individuals in upright, ambulatory and supine state.   
7. Shape: Tetrahedron and ring-shaped devices with a flexural modulus of 48 and 22.5 kilo 
pounds per square inch (KSI) are reported to exhibit a better GRT and 90%-100% retention at 
24hour compared with other shapes 
8.Concomitant drug administration: Anticholinergics like atropine and propantheline, 
opiates like codeine and prokinetic agents like metoclopramide and cisapride affect the 
FDDS.  
9. Biological factors: Diabetes and crohn‟s disease also affect the FDDS.  
Advantages of gastro retentive drug delivery system:  
1. Enhanced bioavailability: The bioavailability of riboflavin CR-GRDF is significantly 
enhanced in comparison to the administration of non-GRDF CR polymeric formulation.   
2. Enhanced first-pass biotransformation: In a similar fashion to the increased efficacy of 
active transporters exhibiting capacity limited activity, the pre-systemic metabolism of the 
tested compound may be considerably increased when the drug is presented to the metabolic 
enymes (Cytochrome P450, in particular CYP3A4) in a sustained manner, rather than by a 
bolus input.   
3. Sustained drug delivery/ reduced frequency of dosing: For drug with relatively short 
biological half-life, sustained and slow input from CR-GRDF may result in a flip-flop 
pharmacokinetics and enable reduced dosing frequency. This feature is associated with 
improved patient compliance and thereby improves therapy.   
4. Targeted therapy for local ailments in the upper GIT: The prolonged and sustained 
administration of the drug from GRDF to the stomach may be advantageous for local therapy 
in the stomach and small intestine as in the case of case of H.pylori induced peptic ulcer.   
5. Reduced fluctuations of drug concentration: Continuous input of the drug following 
CR-GRDF administration produces blood drug concentrations within a narrow range 
compared to the immediate release dosage forms. Thus, fluctuations in drug effects are 
minimized and concentration dependent adverse effects that are associated with peak 
concentrations can be prevented. This feature is of special importance for drugs with a 
narrow therapeutic index.   
6. Extended time over critical (effective) concentration: The sustained mode of 
administration enables extension of the time over a critical concentration and thus enhances 
the pharmacological effects and improves the clinical outcomes.   
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7. Site specific drug delivery: A floating dosage form is a feasible approach for drugs which 
have limited absorption sites in upper small intestine  
8. Minimized adverse activity at the colon: Retention of the drug in the GRDF at the 
stomach minimizes the amount of drug that reaches the colon. Thus, undesirable activities of 
drug in the colon may be prevented as in the case of β-lactam antibiotics.   
9. Administration of a prolonged release floating dosage form tablets or capsules will result 
in dissolution of the drug in gastric fluid. After emptying of the stomach contents, the 
dissolved drug available is for absorption in the small intestine. It is therefore expected that a 
drug will be fully absorbed from the floating dosage form if it remains in solution form even 
at alkaline pH of the intestine.   
10. When there is vigorous intestinal movement and a short transit time as might occur in 
certain type of diarrhea, poor absorption is expected under such circumstances and it may be 
advantageous to keep the drug in floating condition in stomach to get a relatively better 
response.   
11. Many drugs categorized as once-a-day delivery have been demonstrated to have 
suboptimal absorption due to dependence on the transit time of the dosage form making 
traditional extended release development challenging. Therefore, a system designed for 
longer gastric retention will extend the time within which drug absorption can occur in small 
intestine.   
LIMITATIONS OF FLOATING DRUG DELIVERY SYSTEMS 
1. They require a sufficiently high level of fluids in the stomach, for enabling the system to 
float and to work efficiently. This limitation can be overwhelmed by coating the dosage form 
with bioadhesive polymer or alternatively by prescribing the dosage form to be taken up with 
a glass full of water (200-250ml).  
 
2. FDDS are not suitable candidates for drugs with stability or solubility problem in stomach.   
3. Some drugs like nifedipine, which is well absorbed along the entire GI tract and undergoes 
extensive first pass metabolism may not be suitable for FDDS as the slow gastric emptying 
limits the systemic bioavailability.   
4. Drugs with irritant effect on gastric mucosa also limit the applicability of FDDS.   
5. In case of bioadhesive systems, which form electrostatic and hydrogen bonds with the 
mucus, the acidic environment and the thick mucus prevent the bond formation at the mucus 
polymer interface. High turnover rate of the mucus may further aggravate the problem  
6. For swellable systems, the maintenance of their size larger than the aperture of resting 
pylorus for required period of time is the major rate limiting factor. 
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7. Above all, any dosage form designed to stay in stomach during the fasting state should be 
capable of resisting the house keeper waves of phase-III contractions of MMC.   
APPLICATIONS OF FDDS 
1. Sustained drug delivery: HBS systems can remain in the stomach for long periods and 
hence can release the drug over a prolonged period of time. The problem of short gastric 
residence time encountered with an oral CR formulation hence can be overcome with these 
systems. These systems have a bulk density of less than1 as a result of which they can float 
on the gastric contents. These systems are relatively large in size and passing from the pyloric 
opening is prohibited.  Recently sustained release floating capsules of nicardipine 
hydrochloride were developed and were evaluated in vivo. The formulation compared with 
commercially available MICARD capsules using rabbits. Plasma concentration time curves 
showed a longer duration for administration (16hours) in the sustained release floating 
capsules as compared with conventional MICARD capsules (8hours).  
2. Site-specific drug delivery: These systems are particularly advantageous for drugs that are 
specifically absorbed from stomach or the proximal part of the small intestine e.g. riboflavin 
and furosemide. A bilayer-floating capsule was developed for local delivery of misoprostol, 
which is a synthetic analog of prostaglandin E1 used as a protectant of gastric ulcers caused 
by administration of NSAIDs. By targeting slow delivery of misoprostol to the stomach, 
desired therapeutic levels could be achieved and drug waste could be reduced.  
3. Absorption enhancement: Drugs that have poor bioavailability because of site-specific 
absorption from the upper part of the gastrointestinal tract are potential candidates to be 
formulated as floating drug delivery systems, thereby maximizing their absorption.  A 
significant increase in the bioavailability of floating dosage forms (42.9%) could be achieved 
as compared with commercially available LASIX tablets (33.4%) and enteric coated LASIX-
long product (29.5%).  
4. Medopar HBS – containing L-dopa and benserazide-here drug was released and absorbed 
over a period of 6-8 hour and maintain substantial plasma concentration in parkinson‟s 
patients  
5. Cytotech- containing misoprostol, a synthetic prostaglandin-E1 analog, for prevention of 
gastric ulcers caused by NSAIDs. As it provides high concentration of drug within gastric 
mucosa, it is used to eradicate pylori.   
6. 5-Flurouracil has been successfully evaluated in patients with stomach neoplasm.   
7. Developing HBS dosage form for Tacrine provides a better delivery system and reduces its 
GI side effects in Alzheimer‟s patients. 
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  IN-VITRO RELEASE MEHANISMS OF FLOATING SYSTEMS
15, 16
 
The in vitro release mechanisms have been performed for the floating tablets and
 
Depending upon R
2
 and slope values obtained from different models, the best-fit model was 
selected. 
 ZERO ORDER RELEASE 
Drug dissolution from dosage forms that do not disaggregate and release the drug slowly can 
be represented as 
                                      Q = Q0 + K0t 
Where Q is the amount of drug released or dissolved (assuming that release occurs rapidly 
after the drug dissolves), Q0 is the initial amount of drug in solution (it is usually zero), and 
K0 is the zero order release constant. The plot made: cumulative % drug release Vs time (zero 
order kinetic model). 
Zero order drug release mechanism is mainly applicable to dosage forms like transdermal 
systems, coated forms, osmotic systems as well as matrix tablets with low soluble drugs. 
FIRST ORDER RELEASE 
To study the first order release rate kinetics the release rate data were fitted into the following 
equation, 
                           LogC = LogCo- K1t / 2.303 
               where: C  is the amount of drug released at time t, 
                           C o is the initial amount of drug in the solution and 
                           K1 is the first order release constant. 
 
This model is applicable to study of hydrolysis kinetics and to study the release profiles of 
pharmaceutical dosage forms such as those containing water-soluble drugs in porous 
matrices. 
HIGUCHI MODEL  
This model is based on the hypotheses that (i) initial drug concentration in the matrix is much 
higher than drug solubility; (ii) drug diffusion takes place only in one dimension (edge effect 
must be negligible); (iii) drug particles are much smaller than system thickness; (iv) matrix 
swelling and dissolution are negligible; (v) drug diffusivity is constant and (vi) perfect sink 
conditions are always attained in the release environment. 
Higuchi described the release of drugs from insoluble matrix as a square root of time 
dependent process based on Fickian diffusion  
               Q = Kt
1/ 2
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Where, K is the rate constant reflecting the design variables of the system. 
This model is applicable to systems with drug dispersed in uniform swellable polymer matrix 
as in case of matrix tablets with water soluble drug. 
KORSMEYER-PEPPAS Model 
Korsmeyer et al (1983) derived a simple relationship which described drug release from a 
polymeric system. To find out the mechanism of drug release, first 60% drug release data was 
fitted in Korsmeyer-Peppas model: 
                                            Mt/M ∞ = Kt
n
 
Where Mt / M∞ is fraction of drug released at time t, k is the rate constant and n is the release 
exponent. The n value is used to characterize different release mechanisms as given in 
following table for cylindrical shaped matrices 
                    Table No 1: Diffusion exponent and release mechanism 
Diffusion exponent (n) Diffusion mechanism 
< 0.5 Fickian diffusion 
0.5-1 Non- Fickian Transport 
1 Case-II transport 
> 1 Super Case-II  transport 
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Table No 2: Drugs Used in the floating drug delivery systems
17 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SI.NO        Dosage form                               Drug 
1 Floating microspheres Aspirin, griseofulvin, p-nitroaniline, ibuprofen, 
terfinadine and Tranilast 
2 Floating Granules Diclofenac sodium, indomethacin and prednisolone 
3 Films Cinnarazine 
4 Floating capsules Chlordiazepoxide hydrogen chloride, diazepam, 
furosemide, misoprostol, L-dopa, benserazide, 
Urosdeoxycholic acid and pepstatin 
5 Floating tablets and pills Acetaminophen, acetylsalicylic acid, ampicillin, 
amoxicillin trihydrate,  atenolol, diltiazem, flurouracil, 
isosorbide mononitrate, p-amion benzoic  acid, 
theophylline and verapamil 
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Table No 3: Marketed products of floating drug delivery systems
18 
 
                                                            
SI.NO Brand name Drug(dose) Company Remarks 
1 Madopar Levodopa(100mg), 
Benserazide(25mg) 
Roche products Floating,CR 
capsule 
2 Valrelese Diazepam(15mg) Hoffmann-
LaRoche 
Floating capsule 
3 Liquid 
Gaviscon 
Al-
hydroxide(95mg),M
g 
Carbonate(385mg) 
Glaxo smith 
Kline,India 
Effervescent 
floating liquid 
alginate 
preparation 
4 Topalkan Al-Mg antacid Pierre fabre drug Floating liquid 
alginate 
5 Amalgate Al-mg antacid  Floating liquid 
form 
6 Conviron Ferrous sulphate Ranbaxy,India Colloidalgel 
forming FEDS 
7 Cifran OD Ciprofloxacin(1g) Ranbaxy,India Gas-generating 
floating form 
8 Cytotec Misoprostal 
(100mcg/200mcg) 
Pharmaacia Bilayer floating 
capsule 
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                                                     Leukaemia
19 
Leukaemias are a group of cancers of the blood-forming cells. They start in the bone marrow,  
which is spongy tissue that is found in the middle of some of our bigger bones. The abnormal  
cells spread from there into the bloodstream and to other parts of the body. The leukaemia is  
described as lymphoid or myeloid, depending on which type of blood-forming cell in the  
bone marrow the abnormal leukaemia cells develop from 
Types  
Types of leukaemia Leukaemia that develops quickly is called acute leukaemia and 
leukaemia that develops slowly is called chronic leukaemia.  The main types are named 
according to whether they are acute or chronic and also according to which type of blood-
forming cell has become cancerous.   
There are four main types of leukaemia: 
 ● Acute lymphoblastic leukaemia (ALL)  
● Acute myeloid leukaemia (AML)  
● Chronic lymphocytic leukaemia (CLL), Chronic myeloid leukaemia (CML). 
                  Chronic myelogenous (or myeloid) leukemia(CML)
20
                       
Chronic myelogenous leukemia (also called CML or chronic granulocytic leukemia) is a 
slowly progressing blood and bone marrow disease that usually occurs during or after middle 
age, and rarely occurs in children. 
Normally, the bone marrow makes blood stem cells (immature cells) that become mature 
blood cells over time. A blood stem cell may become a myeloid stem cell or a lymphoid stem 
cell. A lymphoid stem cell becomes a white blood cell. A myeloid stem cell becomes one of 
three types of mature blood cells: 
 Red blood cells that carry oxygen and other substances to all tissues of the body. 
 Platelets that form blood clots to stop bleeding. 
 Granulocytes (white blood cells) that fight infection and disease. 
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Fig 10: The process And several steps involved in the formation of red blood cell, 
platelet, or white blood cell. 
 
CLASSIFICATION  
CML is often divided into three phases based on clinical characteristics and laboratory 
findings. In the absence of intervention, CML typically begins in the chronic phase, and over 
the course of several years progresses to an accelerated phase and ultimately to a blast crisis. 
Blast crisis is the terminal phase of CML and clinically behaves like an acute leukemia.  
CHRONIC PHASE 
The first stage of CML is chronic phase. During this phase, patients are usually asymptomatic 
or have only mild symptoms of fatigue, left side pain, joint and/or hip pain, or abdominal 
fullness. The duration of chronic phase is variable and depends on how early the disease was 
diagnosed as well as the therapies used. In the absence of treatment, the disease progresses to 
an accelerated phase. 
ACCELERATED PHASE 
Second stage of CML is considered to be in the accelerated phase, it can be identified by the 
below conditions. The accelerated phase is significant because it signals that the disease is 
progressing and transformation to next phase. Drug treatment often becomes less effective in 
the advanced stages. 
 10–19% myeloblasts in the blood or bone marrow 
47 
 
 >20% basophils in the blood or bone marrow 
 Platelet count <100,000, unrelated to therapy 
 Platelet count >1,000,000, unresponsive to therapy 
 Cytogenetic evolution with new abnormalities in addition to the Philadelphia 
chromosome 
 Increasing splenomegaly or white blood cell count, unresponsive to therapy 
BLAST CRISIS 
Blast crisis is the final phase in the evolution of CML, and behaves like an acute leukemia, 
with rapid progression and short survival. Blast crisis is diagnosed if any of the following are 
present in a patient with CML 
 >20% myeloblasts or lymphoblasts in the blood or bone marrow 
 Large clusters of blasts in the bone marrow on biopsy 
 Development of a chloroma (solid focus of leukemia outside the bone marrow 
SYMPTOMS 
 enlarged spleen causing pain on the left side,  
 malaise,  
 joint and/or hip pain,  
 low-grade fever,  
 increased susceptibility to infections,  
 anemia, and thrombocytopenia with easy bruising 
DIAGNOSIS  
CML is often Diagnosed on the basis of a complete blood count, which shows 
increased granulocytes of all types, typically including mature myeloid 
cells. Basophils and eosinophils are almost universally increased; this feature may help 
differentiate CML from a leukemoid reaction. A bone marrow biopsy is often performed as 
part of the evaluation for CML, and CML is diagnosed by detecting the Philadelphia 
chromosome. This characteristic chromosomal abnormality can be detected by 
routine cytogenetics, by fluorescent in situ hybridization, or by PCR for the bcr-abl fusion 
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gene.
 
Controversy exists over so-called Ph-negative CML, or cases of suspected CML in 
which the Philadelphia chromosome cannot be detected. Many such patients in fact have 
complex chromosomal abnormalities that mask the (9;22) translocation, or have evidence of 
the translocation by FISH or RT-PCR in spite of normal routine karyotyping. The small 
subset of patients without detectable molecular evidence of bcr-abl fusion may be better 
classified as having an undifferentiated myelodysplastic/myeloproliferative disorder, as their 
clinical course tends to be different from patients with CML. 
TREATMENT 
Different types of treatment are available for patients with chronic myelogenous 
leukemia (CML). Some treatments are standard (the currently used treatment), and some are 
being tested in clinical trials. There are six types of standard treatments are available. Which 
are as follows. 
TARGETED THERAPY 
Targeted therapy is a type of treatment that uses drugs or other substances to identify and 
attack specific cancer cells without harming normal cells. Tyrosine kinase inhibitors are 
targeted therapy drugs used to treat chronic myelogenous leukemia. 
CHEMOTHERAPY 
Chemotherapy is a cancer treatment that uses drugs to stop the growth of cancer cells, either 
by killing the cells or by stopping them from dividing. When chemotherapy is taken by 
mouth or injected into a vein or muscle, the drugs enter the bloodstream and can reach cancer 
cells throughout the body (systemic chemotherapy). When chemotherapy is placed directly 
into the cerebrospinal fluid, an organ, or a body cavity such as the abdomen, the drugs mainly 
affect cancer cells in those areas (regional chemotherapy). The way the chemotherapy is 
given depends on the type and stage of the cancer being treated. 
 
BIOLOGIC THERAPY 
Biologic therapy is a treatment that uses the patient‟s immune system to fight cancer. 
Substances made by the body or made in a laboratory are used to boost, direct, or restore the 
body‟s natural defenses against cancer. This type of cancer treatment is also called biotherapy 
or immunotherapy. 
HIGH-DOSE CHEMOTHERAPY WITH STEM CELL TRANSPLANT 
High-dose chemotherapy with stem cell transplant is a method of giving high doses of 
chemotherapy and replacing blood-forming cells destroyed by the cancer treatment. Stem 
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cells (immature blood cells) are removed from the blood or bone marrow of the patient or 
a donor and are frozen and stored. After the chemotherapy is completed, the stored stem cells 
are thawed and given back to the patient through an infusion. These reinfused stem cells grow 
into (and restore) the body‟s blood cells. 
DONOR LYMPHOCYTE INFUSION (DLI) 
Donor lymphocyte infusion (DLI) is a cancer treatment that may be used after stem cell 
transplant. Lymphocytes (a type of white blood cell) from the stem cell transplant donor are 
removed from the donor‟s blood and may be frozen for storage. The donor‟s lymphocytes are 
thawed if they were frozen and then given to the patient through one or more infusions. The 
lymphocytes see the patient‟s cancer cells as not belonging to the body and attack them 
SURGERY 
Splenectomy is surgery to remove the spleen. 
New types of treatment are being tested in clinical trials. 
SIDE EFFECTS: 
Chemotherapy drugs work by attacking cells that are dividing quickly, which is why they 
work against cancer cells. But other cells in the body, such as those in the bone marrow, the 
lining of the mouth and intestines, and the hair follicles, also divide quickly. These cells are 
also likely to be affected by chemotherapy, which can lead to side effects. 
Possible side effects depend on the type and dose of drugs given and the length of time they 
are taken. Some common side effects of chemotherapy include: 
 Hair loss 
 Mouth sores 
 Loss of appetite 
 Nausea and vomiting 
 Increased risk of infection (from low white blood cell counts) 
 Easy bruising or bleeding (from low blood platelet counts) 
 Fatigue (from low red blood cell counts) 
Still, different drugs can have different side effects. For example, vincristine can cause nerve 
damage (neuropathy) leading to numbness, tingling, or even pain or weakness in the hands or 
feet. Lung damage from busulfan is rare, but can be severe.  
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                          Gastrointestinal stromal tumors (GISTs) 
21 
GASTROINTESTIINAL SYSTEM 
The gastrointestinal (GI) system (or digestive system) processes food for energy and rids the 
body of solid waste. After food is chewed and swallowed, it enters the oesophagus, a tube 
that carries food through the neck and chest to the stomach. The oesophagus joins the 
stomach just beneath the diaphragm (the thin band of muscle below the lungs) 
                                  Fig 11: The gastrointestinal system 
 
The stomach is a sac-like organ that holds food and helps the digestive process by secreting 
gastric juice. The food and gastric juices are mixed into a thick fluid called chyme that is then 
emptied into the small intestine. The small intestine continues breaking down the food and 
absorbs most of the nutrients into the bloodstream. This is the longest section of the GI tract, 
measuring more than 20 feet. 
The small intestine joins the large intestine, the first part of which is the colon, a muscular 
tube about 5 feet long. The colon absorbs water and mineral nutrients from the remaining 
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food matter. The waste left after this process goes into the rectum as stool (feces), where it is 
stored until it passes out of the body through the anus. 
GISTs:  
Gastrointestinal stromal tumors (GISTs) are uncommon tumors of the GI tract. These tumors 
start in very early forms of special cells found in the wall of the GI tract, called the interstitial 
cells of Cajal (ICCs). ICCs are cells of the autonomic nervous system, the part of the nervous 
system that regulates body processes such as digesting food. ICCs are sometimes called the 
“pacemakers” of the GI tract because they signal the muscles in the digestive system to 
contract to move food and liquid through the GI tract. 
More than half of GISTs start in the stomach. Most of the others start in the small intestine, 
but GISTs can start anywhere along the GI tract. A small number of GISTs start outside the 
GI tract in nearby areas such as the omentum (an apron-like layer of fatty tissue that hangs 
over the organs in the abdomen) or the peritoneum (the layer of tissue that lines the organs 
and walls of the abdomen). 
SIGNS AND SYMPTOMS 
Most GISTs occur in the stomach or small intestine. These tumors might not cause any 
symptoms unless they are in a certain location or grow to a certain size. Small tumors might 
not cause any symptoms and may be found accidentally when the doctor is looking for some 
other problem. These tumors are often benign. 
GISTs are often found because they cause bleeding into the gastrointestinal (GI) tract. 
Bleeding into the intestines can make bowel movements black and tarry. If the tumor bleeds 
into the stomach or esophagus, a person might vomit blood. Slower bleeding might not cause 
these problems, but over time it can lead to anemia (low red blood cell counts), making a 
person feel tired and weak. 
Other possible symptoms of GISTs are: 
 Abdominal (belly) discomfort or pain 
 A mass or swelling in the abdomen 
 Nausea, vomiting 
 Feeling full after eating only a small amount of food 
 Loss of appetite 
 Weight loss 
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 Problems swallowing (for tumors in the esophagus) 
Sometimes the tumor grows large enough to block the passage of food through the stomach 
or intestine. This is called an obstruction, and it causes severe abdominal pain and vomiting. 
Emergency surgery is often needed to treat the blockage. 
DIAGNOSIS  
Although these tumors are easily detected, there are several methods which are used to 
confirm the GISTs which are as follows 
Imaging tests 
Barium x-rays 
Computed tomography (CT) scan 
Magnetic resonance imaging (MRI) scans 
Positron emission tomography (PET) scan 
Endoscopy 
Biopsy 
 
TREATMENT 
Once a gastrointestinal stromal tumor (GIST) is found and staged, tumors are treated by 
considering their tumor characteristics (such as its size, location, growth rate, and whether it 
has spread) and overall health of a patient. 
The main types of treatment used for GISTs include: 
 Surgery 
 Targeted therapy drugs 
Other treatments, such as chemotherapy and radiation therapy, are used much less often. 
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                                               Literature review 
N Anjali Devi et al
22 
2013 developed a Floating controlled release tablets of Imatinib using 
hydrophilic matrix system by wet granulation technique and found that all the formulations 
were showing good drug release around 98.25- 98.91 where as the best formulation  released 
the maximum amount of drug around 99.46% by zero-order release kinetics in  12 hours. 
Mudgal Vinod Kumar et al
23
 2012 developed a sustained release floating system of 
Ciprofloxacin by direct compression method and coated with polymeric material Eduragit 
30D and ATEC are used as film formers and plasticizers and reported that the optimized 
formulation was floating within 20 min and remained buoyant for 13hours and the drug 
action was sustained for 20 hours. 
E Sathish Reddy et al
24
 2012 developed a sustained release floating tablets of Ciprofloxacin. 
Sodium bicarbonate was used in the formulations as a source of Carbondioxide. The matrix 
type of system was prepared with the help of swell-able polymer 
hydroxypropylmethylcellulose k15M and was formulated in such a way that when in contact 
with the acidic gastric contents, CO2 was liberated and got entrapped in swollen hydrocolloid, 
which provides buoyancy to the dosage forms. More over DL-methionine was added as a 
hepato- protective agent that makes the formulation a unique one. 
Madhusudan Rao et al
25
 2012 developed Gastro retentive formulation of Cefuroximeaxetil 
by using hydrophilic polymers such as HPMC K15M, HPMC K4M and observed that all the 
formulations followed fickian diffusion. And have a gastric residence time of 6 hours in fed 
state. 
Sonia dhiman et al
26
 2012 formulated controlled release floating type gastro retentive tablets 
of famotidine using HPMC K15M as a polymer and reported that targeted delivery of the 
drug provides an effective and safe therapy with reduced dose and duration of therapy. The 
floating drug delivery system was developed by effervescent approach. 
K. Karuna Kar et al
27
 2011 developed floating matrix tablets of Lamivudine to prolong the 
gastric residence time and to increase its bio availability, tablets were prepared by using 
HPMC E15 and xanthan gum, and found that the drug release is Korsmeyer Peppas model. 
And found that the tablet hardness has little or no effect on drug release kinetics. 
Pramod Patil et al
28
 2011 developed and desigined  Floating tablets of Olfloxacin to prolong 
gastric residence time after oral administration by using wet granulation method by 
incorporating natural polymers like guar gum, locust beam gum along with HPMC K100M  
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and found that the drug release from the best formulation was uniform throughout the study 
and follows Higuchi kinetic model. 
Gada et al
29
 2011 designed and developed floating tablets by direct compression technique 
using polymers like HPMC K4M, HPMC K15M and HPMC K100M as gel forming 
polymers , and concluded that the floating tablets are the systems which are retained in the 
body for a longer period of time and there by increases the drug bio availability. 
Kurnal patel M et al
30
 2011 Formulated and evaluated a gastro retentive drug delivery 
system of Mebendazole by wet granulation technique with several additives like chitosan, 
HPMC and stearic acid and studied the effect of citric acid and stearic acid on drug release 
profiles and floating properties and concluded that the addition stearic acid decreases the 
dissolution properties due to its hydro phobic nature. 
Afsar c.shaikh et al
31
 2011 formulated floating bio-adhesive tablets of Tramadol by Direct 
compression method using various amounts of Carbopol, HPMC,  and concluded that the 
muco adhesion and hydrodynamic balance are playing an important role in the controlled 
release of drug. 
Burpute S.S et al
32 
2011 developed floating tablets of Nizatidine employing two different 
grades of HPMC,  and other polymers incuding carbopol and also the gas forming agents and 
reported that the tablets swelled axially and radially during the study. 
Singh L. P et al
33
 2011 developed a dosage form to prolong the release of the drug from the 
dosage form and improve drug absorption in upper GIT and stomach, using effverscent 
technique  and concluded that the gastric retention increases the absorption of the drug with 
narrow therapeutic index. 
N. Damadoran et al
34
 2011 developed bi-layered floating tablets of Theophylline  using wet 
granulation technique, using polymers like HPMC and Sodium carboxy methyl cellulose and 
found that the combination of HPMC and methyl Cellulose can sustain the release of the drug 
and the drug release followed first order kinetics. 
Anilkumar Jet et al
35
 2010 formulated an oral floating tablet of Cephlaxin  using the 
hydrophilic polymer HPMC and gas generating agents,  by means of wet granulation method 
and concluded that the drug action is controlled for a period of 12 hours. 
ChandraShekar B et al
36
 2010 designed and developed a gastro retentive drug delivery 
system of Ketoconazole by direct compression technology, by incorporating several 
hydrophilic polymers and found out that the drug release  was around 24 hours and obeying 
mixed order kinetics. 
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Sharada Shinde et al
37
 2010 developed a floating matrix tablets of Salbutamol Sulphate by 
wet granulation method by using HPMC K100M and gas generating agents such as sodium bi 
carbonate and citric acid and concluded that the initial burst effect can‟t be retarded by using 
high level of HPMC. 
Vinod. K. R et al
38
 developed controlled release Imatinib mesylate oral dosage form which 
can retain the drug in the stomach for prolonged duration and to achieve therapeutic levels 
over an extended period of time, by direct compression method. The tablets were also 
evaluated for in vitro drug release in 0.1N Hcl for 12 hrs in USP Type II dissolution 
apparatus. In order to determine the mode of release, the data was fitted into various kinetic 
models and the optimized formulation followed Korsmeyer peppas model and the „n‟ value 
was greater than one indicated super case II mechanism of drug release. The radiographic 
pictures of the rabbits confirm the in vivo mucoadhesion in the stomach for 6h. 
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AIM 
To design and formulate a gastro-retentive drug delivery system of Imatinib. 
 
OBJECTIVES 
The objectives of the present work include:  
1. Drug-polymer interaction studies  
2. Preparation of Gastro-retentive tablets of  IMATINIB  by direct compression 
technique. 
3. Evaluation of blends for pre and tablets for  post compression parameters.  
4. Physical parameters like hardness, friability, weight variation, drug content 
uniformity. 
5. In-Vitro evaluation of matrix tablets for the release characteristics.  
6. To study the release kinetics of developed formulations. 
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                                              PLAN OF WORK 
The Plan of research work has been scheduled as: 
1. Preformulation studies: 
 Compatability studies 
 Solubility 
 Angle of repose 
 Bulk density 
 Tapped density 
 Compressibility index 
 Hausners ratio 
2. Development of gastroretentive dosage form of Imatinib 
3. Evaluation of Formulated dosage form 
 Hardness 
 Friability 
 Weight variation 
 Content uniformity 
 In-Vitro buoyancy studies 
 Swelling index 
 In-Vitro dissolution studies 
 Pharmacokinetic modelling 
 Stability studies of optimized formulation 
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                           MATERIALS AND EQUIPMENTS 
       
                                    Table 4: Materials used in the study 
Name of chemical Source 
Imatinib Hetero drugs pvt Ltd, Hyderabad. 
HPMCK15 Lara drugs pvt Ltd, Hyderabad. 
Carbapol Lara drugs pvt Ltd, Hyderabad. 
Chitosan Lara drugs pvt Ltd, Hyderabad. 
Sodium bi carbonate Lara drugs pvt Ltd, Hyderabad. 
Citric acid Lara drugs pvt Ltd, Hyderabad. 
Magnesium stearate Lara drugs pvt Ltd, Hyderabad. 
MCC Lara drugs pvt Ltd, Hyderabad. 
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                                  Table 5 :  Equipments used in the study 
SI.NO Equipments Manufacturer 
1 Weighing balance Sartorius 
2 UV – visible spectrophotometer 
Labindia – 3200, Double beam 
Spectrophotometer 
3 FT – IR spectrophotometer MB 104 Shimadzu corporation,japan 
4 Dissolution test apparatus 
Labindia Dissolution tester, DISSO 
14000 
5 Tablets Punching machine Cadmach, Ahmedabad. 
6 Humidity chamber Sigma instruments, Mumbai 
7 Friabilator Labindia Friability tester, FT 1020. 
8 Tapped density tester Labindia Tap density tester, TD 1025. 
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                                            DRUG PROFILE
 
IMATINIB: 39 
AVAILABLE FORMS:  
Imatinib mesylate, 
Imatinib methasulfonate. 
THERAPEUTIC CATEGORY: 
Antineoplastic Agent, 
Protein Kinase Inhibitor. 
STRUCTURE 
                Fig 12: Molecular structure of Imatinib 
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CHEMICAL NAME 
 4-[(4-methylpiperazin-1-yl)methyl]-N-(4-methyl-3-{[4-(pyridin-3-yl)pyrimidin-2-
yl]amino}phenyl)benzamide 
MOLECULAR WEIGHT: 
493.60274[g/mol] 
MOLECULAR FORMULA:  
  C29H31N7 O
 
 
DESCRIPTION:  
It is a white to off-white amorphous solid. 
APPEREANCE:  
 White amorphous 
SOLUBILITY:  
It is soluble in 0.1N HCL, DMSO and Water. 
MELTING POINT:  
Melting point is around 226
0
C 
MECHANISM OF ACTION: 40 
 
Imatinib is a 2-phenylaminopyrimidine derivative that functions as a specific inhibitor of a 
number of tyrosine kinase enzymes. It occupies the TK active site, leading to a decrease in 
activity.
 
There are a large number of TK enzymes in the body, including the insulin receptor. Imatinib 
is specific for the TK domain in abl (the Abelson proto-oncogene), c-kit and PDGF-
R (platelet-derived growth factor receptor). 
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In chronic myelogenous leukemia, the Philadelphia chromosome leads to a fusion protein 
of abl with bcr(breakpoint cluster region), termed bcr-abl. As this is now a constitutively 
active tyrosine kinase, imatinib is used to decrease bcr-abl activity. 
The active sites of tyrosine kinases each have a binding site for ATP. The enzymatic 
activity catalyzed by a tyrosine kinase is the transfer of the terminal phosphate from ATP 
to tyrosine residues on its substrates, a process known as protein tyrosine phosphorylation. 
Imatinib works by binding close to the ATP binding site of bcr-abl, locking it in a closed or 
self-inhibited conformation, and therefore inhibiting the enzyme activity of the protein semi-
competitively.
 
This is fact explains why many BCR-ABL mutations can cause resistance to 
imatinib by shifting its equilibrium toward the open or active conformation. 
Imatinib is quite selective for bcr-abl – it does also inhibit other targets mentioned above (c-
kit and PDGF-R), but no other known tyrosine kinases. Imatinib also inhibits the abl protein 
of non-cancer cells but cells normally have additional redundant tyrosine kinases which allow 
them to continue to function even if abl tyrosine kinase is inhibited. Some tumor cells, 
however, have a dependence on bcr-abl. Inhibition of the bcr-abl tyrosine kinase also 
stimulates its entry in to the nucleus, where it is unable to perform any of its normal anti-
apoptopic functions. 
The Bcr-Abl pathway has many downstream pathways including the Ras/MapK pathway, 
which leads to increased proliferation due to increased growth factor-independent cell 
growth. It also affects the Src/Pax/Fak/Rac pathway. This affects the cytoskeleton, which 
leads to increased cell motility and decreased adhesion. The PI/PI3K/AKT/BCL-2 pathway is 
also affected. BCL-2 is responsible for keeping the mitochondria stable; this suppresses cell 
death by apoptosis and increases survival. The last pathway that Bcr-Abl affects is the 
JAK/STAT pathway, which is responsible for proliferation.  
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                     Fig 13: Mechanism of action of Imatinib 
 
 
 
PHARMACOKINETIC PROPERTIES41 
ABSORPTION 
After oral intake, imatinib is rapidly absorbed from the gut, because of its rapid dissolution at 
acidic pH. Imatinib should be taken with a meal and water to reduce gastrointestinal side 
effects. However, a high fat meal can prolong the uptake and therefore the time to reach a 
maximum plasma concentration (tmax). Under normal conditions, the maximal plasma 
concentration of approximately 1.9 μg/ml is reached after 2–4 hours. After repeated 
administration of 400 mg of imatinib per day, the mean plasma concentration in steady state 
is ≥1 μmol/l after 24 hours. 
Absolute bioavailability is estimated to be almost complete, but can be significantly lower in 
some cases as a result of limited absorption. Bioavailability is unaffected by Normal meal.  
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PROTEIN BINDING 
Imatinib is highly protein bound. It binds mostly to albumin. Protein binding is 
approximately 95% . Imatinib also binds to α1-acid-glycoprotein in vitro and in vivo. But 
binding to α1-acid-glycoprotein binding does not influence the activity of imatinib. 
METABOLISM 
Imatinib is metabolized by the cytochrome P450 (CYP) isoenzymes in the gut wall and liver. 
The metabolism is mainly mediated by CYP3A4 and CYP3A5, but other CYP isoenzymes 
such as CYP1A2, CYP2D6, CYP2C9, and CYP2C19 also play minor roles. The main 
metabolite is the N-demethylated piperazine derivate. Based on in vitro studies, this 
metabolite has potency comparable to that of the parent compound. The exposure measured 
as a percentage of the area under the concentration–time curve in plasma of the N-
demethylated piperazine derivate is approximately 10%–15% of that of imatinib. In addition, 
imatinib and its N-demethylated piperazine derivate are N-oxidized in the liver. 
ELIMINATION 
On average, 75% of the dose of imatinib undergoes biotransformation. Imatinib has a 
terminal half-life of 19 hours (range, 14–23 hours), while its main metabolite has a terminal 
half-life of 40 hours (range, 30–50 hours) . Excretion takes place mainly via the bile, 68% as 
metabolites and 20% as parent compound. Renal excretion is low, as only 13% of the 
metabolites and 5% of the parent compound are excreted via the kidneys  
PHARMACODYNAMIC PROPERTIES 
The pharmacokinetic–pharmacodynamic relationships of imatinib have not been extensively 
studied. However, there seems to be a relationship between dose and likelihood of tumor 
response. In CML, patients treated at a dose <400 mg/day showed a significantly lower 
cytogenic response than patients treated with a higher dose . Early trials showed no 
significant positive effect of a starting dose >400 mg/day in most patients if adverse effects 
are considered. Therefore, it was concluded that a 400-mg/day dose would be optimal in most 
patients . However, in patients with an unsatisfactory response to the 400-mg/day dose, dose 
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escalation to 600 mg/day or 800 mg/day can be effective without resulting in greater adverse 
effects. At a dose >800 mg/day, toxic effects are significantly greater without greater activity. 
In patients with CML, the overall survival rate after 60 months is estimated to be 
approximately 89% after treatment with imatinib. The progression-free survival rate at 60 
months was approximately 83% (95% confidence interval, 79%–87%) in the same study . 
In patients with GISTs, the progression-free survival duration after treatment with imatinib is 
estimated to be approximately 2 years. A European trial in GIST patients showed that the 
progression-free survival rate was significantly higher in patients who started on 400 mg 
twice daily than in patients treated with 400 mg daily (56% versus 50%) . 
DOSE  
100 to 400 mg daily, in divided doses. 
SIDE EFFECTS 
The most common side effects include: feeling sick (nausea), diarrhoea, headaches, leg 
aches/cramps, fluid retention, visual disturbances, itchy rash, lowered resistance to infection, 
bruising or bleeding, loss of appetite;
 
weight gain, reduced number of blood cells 
(neutropenia, thrombocytopenia, anemia), headache, and edema. 
Severe congestive cardiac failure is an uncommon but recognized side effect of imatinib and 
mice treated with large doses of imatinib show toxic damage to their myocardium. 
If imatinib is used in prepubescent children, it can delay normal growth, although a 
proportion will experience catch-up growth during puberty. 
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PRECAUTIONS42 
There are several tips advised for a person during the Administration of Imatinib, which are 
as follows.    
 Take this medication after a meal with a large glass of water to reduce upset 
stomach.  Take this medication at about the same time each day. 
 If you miss a dose of this medication, do not take the missed dose at all and do not 
double the next one.  Instead, go back to your regular dosing schedule and check with 
your health care provider. 
 You may be at risk of infection so try to avoid crowds or people with colds and those 
not feeling well, and report fever or any other signs of infection immediately to your 
health care provider. 
 Wash your hands often.  
 Drink at least two to three quarts of fluid every 24 hours, unless you are instructed 
otherwise. 
 Use an electric razor and a soft toothbrush to minimize bleeding. 
 Avoid contact sports or activities that could cause injury. 
 In general, drinking alcoholic beverages should be kept to a minimum or avoided 
completely.  You should discuss this with your doctor. 
 Get plenty of rest.  
 Maintain good nutrition. 
 If you experience symptoms or side effects, be sure to discuss them with your health 
care team.  They can prescribe medications and/or offer other suggestions that are 
effective in managing such problems. 
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INTERACTIONS 
 There are several no of drug interactions detected for Imatinib, in some cases both drugs 
action will get increased and may leads to toxicity where as in some cases the drug action 
will get reduced, the detailed drug interactions were classified in the tables below. 
                Table 6: Drug Interactions with Increased Drug action. 
SI.NO DRUG  INTERACTION 
1 Acenocoumarol Imatinib may increase the anticoagulant effect of 
acenocoumarol. 
2 Acetaminophen Increased hepatic toxicity of both agents 
3 Anisindione Imatinib may increase the anticoagulant effect of anisindione. 
4 Atorvastatin Imatinib, a strong CYP3A4 inhibitor, may increase the effect 
and toxicity of atorvastatin by decreasing its metabolism. 
5 Bromazepam Imatinib, a strong CYP3A4 inhibitor, may increase the serum 
concentration of bromazepam by decreasing its metabolism. 
6 Cerivastatin Imatinib, a strong CYP3A4 inhibitor, may increase the serum 
concentration of cerivastatin by decreasing its metabolism. 
7 Clarithromycin The macrolide, clarithromycin, may increase the serum 
concentration of imatinib. 
8 Cyclosporine Imatinib increases the effect and toxicity of cyclosporine. 
9 Dicumarol Imatinib may increase the anticoagulant effect of dicumarol. 
10 Erythromycin The macrolide, erythromycin, may increase the serum 
concentration of  Imatinib. 
11 Itraconazole Itraconazole may increase the levels of imatinib. 
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12 Josamycin The macrolide, josamycin, may increase the serum 
concentration of imatinib. 
13 Ketoconazole Ketoconazole may increase the levels of imatinib. 
14 Lovastatin Imatinib, a strong CYP3A4 inhibitor, may increase the effect 
and toxicity of lovastatin by decreasing its metabolism. 
23 Verapamil Imatinib, a strong CYP3A4 inhibitor, may increase the serum 
concentration of Veramapil, a CYP3A4 substrate, by 
decreasing its metabolism and clearance. 
15 Nifedipine Imatinib increases the effect and toxicity of nifedipine 
16 Simvastatin Imatinib, a strong CYP3A4 inhibitor, may increase the effect 
and toxicity of simvastatin by decreasing its metabolism. 
17 Tamoxifen Imatinib may increase the serum concentration of Tamoxifen 
by decreasing its metabolism and clearance. 
18 Topotecan Imatinib, may increase the bioavailability and serum 
concentration of oral Topotecan 
19 Tramadol Imatinib may increase Tramadol toxicity by decreasing 
Tramadol metabolism and clearance 
20 Trastuzumab Trastuzumab may increase the risk of neutropenia and 
anemia. 
21 Trazodone The CYP3A4 inhibitor, Imatinib, may increase Trazodone 
efficacy/toxicity by decreasing Trazodone metabolism and 
clearance. 
22 Vardenafil Imatinib, a strong CYP3A4 inhibitor, may reduce the 
metabolism and clearance of Vardenafil 
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24 Vincristine Imatinib, a strong CYP3A4 inhibitor, may increase the serum 
concentration of Vincristine by decreasing its metabolism. 
25 Vinorelbine Imatinib, a strong CYP3A4 inhibitor, may increase the serum 
concentration of Vinorelbine by decreasing its metabolism. 
26 Voriconazole Voriconazole, a strong CYP3A4 inhibitor, may increase the 
serum concentration of imatinib by decreasing its 
metabolism. 
27 Warfarin Imatinib may increase the anticoagulant effect of warfarin 
increasing the risk of bleeding. 
28 Zonisamide Imatinib, a strong CYP3A4 inhibitor, may increase the serum 
concentration of zonisamide by decreasing its metabolism. 
29 Zopiclone Imatinib, a strong CYP3A4 inhibitor, may increase the serum 
concentration of zopiclone by decreasing its metabolism. 
30 Dantrolene Imatinib may increase the serum concentration of dantrolene 
by decreasing its metabolism. 
31 Pimozide Pimozide may increase the effect and toxicity of imatinib. 
32 Tamsulosin Imatinib increases its action 
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                  Table 7: Drug Interactions with Decreased drug action. 
SI.NO DRUG INTERACTION 
1 Aprepitant Aprepitant may change levels of the chemotherapy agent, 
imatinib. 
2 Carbamazepine Carbamazepine, a strong CYP3A4 inducer, may increase the 
metabolism of imatinib. 
3 Dexamethasone Dexamethasone may decrease levels of imatinib. 
4 Ethotoin The hydantoin decreases the levels of imatinib. 
5 Fosphenytoin The hydantoin decreases the levels of imatinib. 
6 Mephenytoin The hydantoin decreases the levels of imatinib. 
7 Phenobarbital The Phenobarbital decreases the level of imatinib. 
8 Phenytoin The hydantoin decreases the levels of imatinib 
9 Rifampin Rifampin decreases levels of imatinib 
10 St. John's Wort St. John's Wort decreases levels of imatinib 
11 Tacrolimus The strong CYP3A4 inhibitor, Imatinib, may decrease the 
metabolism and clearance of Tacrolimus, 
12 Tadalafil Imatinib may reduce the metabolism of Tadalafil. 
Concomitant therapy should be avoided if possible due to 
high risk of Tadalafil toxicity. 
13 Telithromycin Co-administration may result in altered plasma 
concentrations of Imatinib and/or Telithromycin. 
14 Temsirolimus Imatinib may inhibit the metabolism and clearance of 
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Temsirolimus. 
15 Tramadol Imatinib may decrease the effect of Tramadol by decreasing 
active metabolite production 
16 Tolterodine Imatinib may decrease the metabolism and clearance of 
Tolterodine 
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A.HYPERMELLOSE 
SYNONYMS 
Benecel MHPC; E464; hydroxyl-pro-pyl methylcellulose; HPMC; Hypro-mellosum; 
Methocel; methylcellulose propylene glycol ether; methyl hydroxypropylcellulose; Metolose; 
MHPC; Pharmacoat; Tylopur; Tylose MO. 
STRUCTURAL FORMULA 
                                  Fig 14: Structure of Hypermellose 
 
 
NONPROPRIETARY NAMES 
BP: Hypromellose 
JP: Hypromellose 
PhEur: Hypromellose 
USP: Hypromellose 
CHEMICAL NAME 
Cellulose  hydroxyl-pro-pyl methyl ether. 
DESCRIPTION 
Hypromellose is an odorless and tasteless, white or creamy-white 
fibrous or granular powder. 
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FUNCTIONAL CATEGORY 
Bio-adhesive material; coating agent; controlled-release agent; dispersing agent; dissolution 
enhancer; emulsifying agent; emulsion stabilizer; extended-release agent; film-forming agent; 
foaming agent; granulation aid; modified-release agent; mucoadhesive; release-modifying 
agent; solubilizing agent; stabilizing agent; suspending agent; sustained-release agent; tablet 
binder; thickening agent; viscosity-increasing agent.  
APPLICATIONS 
Hypromellose is widely used in oral, ophthalmic, nasal, and topical Pharmaceutical 
formulations. In oral products, hypromellose is primarily used as a tablet binder, in film-
coating and as a matrix for use in extended release tablet formulations. Concentrations 
between 2% and 5% w/w may be used as a binder in either wet- or dry-granulation processes. 
High-viscosity grades may be used to retard the release of drugs from a matrix at levels of 
10–80% w/w in tablets and capsules. Hypromellose is also used in liquid oral dosage forms 
as a suspending and/or thickening agent at concentrations ranging from 0.2.5% to 5.0%. 
Hypromellose is also used as a suspending and thickening agent in topical formulations. 
Compared with methylcellulose, hypromellose produces aqueous solutions of greater clarity, 
with fewer undissolved fibers present, and is therefore preferred in formulations for 
ophthalmic use. Hypromellose at concentrations between 0.45–1.0% w/w may be added as a 
thickening agent to vehicles for eye drops and artificial tear solutions. It is also used 
commercially in liquid nasal formulations at a concentration of 0.1%. Hypromellose is used 
as an emulsifier, suspending agent, and stabilizing agent in topical gels and ointments. As a 
protective colloid, it can prevent droplets and particles from coalescing or agglomerating, 
thus inhibiting the formation of sediments. 
STABILITY AND STORAGE CONDITIONS 
Hypromellose powder is a stable material, although it is hygroscopic After drying. Solutions 
are stable at pH 3–11. Hypromellose undergoes a reversible sol–gel transformation upon 
heating and cooling, respectively. The gelation temperature is 50–908C, depending upon the 
grade and concentration of material. For temperatures below the gelation temperature, 
viscosity of the solution decreases as temperature is increased. Beyond the gelation 
temperature, viscosity increases as temperature is increased. Aqueous solutions are 
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comparatively enzyme-resistant, providing good viscosity stability during long-term storage. 
However, aqueous solutions are liable to microbial spoilage and should be preserved with an 
antimicrobial preservative: when hypromellose is used as a viscosity-increasing agent in 
ophthalmic solutions, benzalkonium chloride is commonly used as the preservative. Aqueous 
solutions may also be sterilized by autoclaving; the coagulated polymer must be redispersed 
on cooling by shaking. Hypromellose powder should be stored in a well-closed container, in a 
cool, dry place. 
INCOMPATABILITIES 
Hypromellose is incompatible with some oxidizing agents. Since it is Nonionic, 
hypromellose will not complex with metallic salts or ionic organics to form insoluble 
precipitates. 
B. CARBOMER 
NONPROPRIETARY NAMES 
BP: Carbomers 
PhEur:Carbomers 
USP-NF:Carbomers 
 SYNONYMS 
Acropyl; Acritamer; Acrylic acid Polymer; Carbomera; Carbopol; Carboxy Polymethylene; 
Polyacrylic acid; Carboxyvinyl Polymer; Pemulen; Tego Carbomer. 
CHEMICAL NAME 
CARBOMER [9003-01-4] 
Note that alternative CAS registry numbers have been used for carbomer 934([9007-16-
3]),940 (9007-17-4]) and 941([9062-04-08]). The CAS registry number [9007-17-4] has also 
been used for carbomer. 
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EMPIRICAL FORMULA AND MOLECULAR WEIGHT 
Carbomers are synthetic high molecular weight polymers of acrylic acid that are cross linked 
with either allyl sucrose or allyl ethers of pentaerythritol. They contain between 52% and 
68% of carboxylic acid(COOH) groups calculated on the dry basis. The BP2009 and PhEur 
6.4 have a single monograph describing individual carbomer grades that vary in aqueous 
viscousity, polymer type, and polymerization solvent. The molecular weight of carbomer is 
theriotically estimated as 7*10
5 
 to 4*10
9
 . In an effort to measure the molecular weight 
between cross-links ,Mc,reserchers have extended the network theory of elasticity to swollen 
gels and have utilized the inverse relationship between the elastic modulus and  Mc 
(1-3) 
  
.Estimated  Mc values of 237600g/mol for carbomol 941 and of 104 400g/mol for carbopol 
940 have been reported . In general ,carbomer polymers with lower viscousity and lower 
rigidity will have higher  Mc values.Conversily ,high-viscousity,more rigid carbomer 
polymers will have lower Mc values. 
STRUCTURAL FORMULA 
Carbomer polymers are formed from repeating units of acrylic acid.  The polymer chains are 
crosslinked with allyl pentaerythritol.  
FUNCTIONAL CATEGORY 
Bioadhesive material; controlled-release agent  
Emulsifying agent;  
Emulsion stabilizer;  
Rheology modifier; 
Stablizer;  
Suspending agent and tablet binder 
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APPLICATIONS 
Carbomers are used in liquid or semisolid pharmaceutical formulation as rheology modifiers. 
Formulations include creams, gels, lotions and ointments for use in ophthalmic,
 
rectal, topical
 
and vaginal
 
preparations. carbomer grades with residual benzene content greater than 2ppm 
do not meet the specifications of the PhEur 6.4 monograph. However, carbomer having low 
residual of other solvent than the ICH-defined class IOVI solvents may be used in europe.  
Carbomer having low resuidals of ethl acetate, such as carbopol 971 P NF or carbopol 
974PNF may be used in oral preparations, in suspensions, capsules or tablets. In tablet 
formulations, carbomer are used as controlled release agents and/or as blinders. In contrast to 
linear polymers, higher viscosity does not results in slower drug release with carbomers . 
Lightly cross linked carbomers are generally more efficient in controlling drug   release than 
highly cross linked carbomers. In wet granulation processes, water, solvents or their mixtures 
can be used as the granulating fluid. The tackiness of wet mass may be reduced by including 
talc in the formulation or by adding certain cationic species to the granulating field. However 
the presence of cationic salts may accelerate the drug release rates and release rates and 
reduce bioadhesive properties. carbomer polymers have also been investigated in the 
preparation of sustained –release  matrix beads, an enzime inhibitors of intestinal proteass in 
peptide –containing dosage forms as a bioadhesive for a cervical patch  and for intranasally 
administered microspheres in magnetic granules for site-specific drug delivery to the 
esophagus, and  in oral mucoadhesive controlled drug delivery systems. Carbomer 
copolymers are employed as emulasifying agents in the preparation of the oil-in water 
emulsion for external administrarion. carbomer 951 has been investigated as a viscosity 
increasing aid in the preparation of multiple emulsion microspheres. Carbomers are also used 
in cosmetics. Therapeutically carbomer formulation have been provided efficacious in 
improving symptoms of moderate to severe dry eye syndrome  
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                                          Table 8:  Use of carbomers  
Use Concentration 
Emulsifying agent 
Gelling agent 
Suspending agent 
Table blinder 
Rate Controlling agent 
0.1-0.5 
0.5-2.0 
0.5-1.0 
0.75-3.0 
5.0-30.0 
 
 DESCRIPTION 
Carbomers are white-colored,‟fluffy‟,acidic, hygroscopic powders with a characteristics 
slight oder.a granular carbomer is also available. 
PHARMACOPEIAL SPECIFICATIONS 
The USP32-NF27 has several monographs for different carbomer grades, while the BP 2009 
and PhEur 6.4 have only a single monograph. 
The USP32-NF27 lists three umberlla monographs carbomer copolymer, carbomer 
homopolymer and carbomer interpolymer, which separates carbomer products, based on 
polymer structure and apply to prodycts not polymerized in benzene. The differentiation 
within each umberlla monograph is based on viscousity characterastics. 
The USP32-NF27 also lists monographs for carbomer 934,934p,940 and 941,which are 
manufactured usuing benzene. Currently these monographs can apply to products 
manufactured both with and without  the use of benzene. Effectively  from january 1 ,2011 
products manufactured without the use of benzene will be officially tilted carbomer 
homopolymer provided they comply with the carbomer 1342,which applies to carbomer 
copolymers manufactured using benzene. 
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Carbomer polymers are also covered either individually or together in other pharmacopeias. 
Note that unless otherwise indicated ,the test limits shown above apply to all grades of 
carbomer. 
TYPICAL PROPERTIES 
Acidity/alkalinity 
pH=2.5-4.0 for 0.2% w/v aqueous dispersion; 
pH=2.5-3.0 for acrypol  1% w/v aqueous dispersion; 
Density (bulk) 0.2g/cm
3
(powder);0.4g/cm
3
(granular) 
Density (tapped) 0.3g/cm
3
(powder);0.4g/cm
3
(granular) 
Dissociation constant pKa =6.0+0.5 
Glass transition temperature 100-105
0
c 
Melting point :decomposition occurs within 30 minutes at 260
0
c. 
moisture content typical water content is upto 2% w/w. however ,carbomers are hygroscopic 
and a typical equlibrium moisture content at 25
0
c and 50% relative humidity is 8-10% w/w. 
the moisture content of carbomer does not affect its thickness efficiency ,but an increase in 
the moisture content makes the carbomer more difficultto handle because it is less readily 
dispersed. 
STABILITY AND STORAGE CONDITIONS 
Carbomers are stable, hygroscopic material that may be heated at temperature below 104
0
c 
and 2 hours without affecting their thickening efficiency. However exposure to excessive 
temperatures can result in discoloration and reduced stability. Complete decomposition 
occurs with hearing for ong fungi.  In contrast microorganisms grow well in unpreserved 
aqueous dispersion and therefore an antimicrobial preservative such as 0.1% w/v thimerosal 
should be added. The w/v propylene Or 0.1%w/v thimerosal the addition of certain 
antimicrobials such as benzalkonium chloride or sodiam benzonite in high concentration can 
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cause cloudiness And a reduction in viscosity of carbomer dispersions. Aqueous gels may be 
sterilized by autoclaving with minimal changes in viscosity pH ,provided care is taken to 
exclude oxygen from the system or by gamma radiations although this technique may 
increase the viscosity of formulation. At room temperature carbomer disperse maintain their 
viscosity during storage for prolonged periods. Similarly dispersion viscosity is maintained or 
only slightly reduced  at elevated storage temperature if an antioxidant is include in the 
formulation or if the dispersion is stored  protected from the light . exposture to light causes 
oxidation that is reflected in a decrease in dispersion viscosity stability to light  may be 
improved by the addition  of 0.05-0.1% w/v edetic  acid. 
Carbomer powder should be stored in an alright corrosion resistant container and protected 
from moisture. The use of glass plastic or resin-lined container is recommended for the 
storage of formulation containing carbomer. 
INCOMPATIBILITIES 
Carbomers are discolored by resorcinol and are incompatible with phenol, cationic polymers, 
Strong acids and high levels of electrolytes. Certain antimicrobial adjuvants should also be 
avoided or 
Used at low levels, see section 11. Trace levels of iron and other transition metals can 
catalytically degrade carbomers dispersions. 
Certain amino-functional actives from complexes with carbomers; often this can be prevented 
by adjusting the pH of the dispersion and/or te solubility perameter by using appropriate 
alcohols and polyols. 
Carbomers also form pH- dependent complexes with certain polymeric 
excipients.Adjustment of pH and/or solubility perameter can also work in this sitation. 
 SAFTEY 
Carbomers are used extensively in nonparenteral products, particularly topical liquid and 
semisolid preparations. Grades polymerized in ethyl acetate may also be used in oral 
formulations; see section 18. There is no evidence of systemic absorption of carbomer 
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polymers following oral administration.
 (56)
 Acute oral toxicity studies in animals indicate that 
carbomer934p has a low oral toxicity, with doses up to 8g/Kg being administered to dogs 
without fatalities occurring. Carbomers are generally regarded as essentially nontoxic and 
nonirritant materials there is no evidence in humans of hypersensitivity reactions to 
carbomers used topically 
 HANDLING PRECAUTIONS 
Observe normal precautions appropriate to the circumstances and quantity of material 
handled. Excessive dust generation should be minimized to avoid the risk of explosion 
(lowest explosive concentration is 130 g/m
3 
). Carbomers dust is irritating to the eyes mucous 
membranes, and respiratory tract. In the event of eye contact with caroler dust. Saline should 
be used for eye irrigation purpose. Gloves, eye protection, and a dust respirator are 
recommended during handling. A solution of electrolytes (sodium chloride) is recommended 
for cleaning equipment after processing carbomers.  
C. CHITOSAN 
NONPROPRIETARY NAMES 
BP: Chitosan hydrochloride 
phEur:  Chitosan hydrochloride 
SYNONYMS 
2-Amino2-deoxy(1,4)-β-D-glucopyranan;chitosanihydrochloridum;deacetylated 
chitin;deacetylchitin;β-1,4-poly-D-glucosamine;poly-D-glucosamine;poly-(1,4-β-D-
glucopyranosamine). 
EMPERICAL FORMULA AND MOLECULAR WEIGHT 
Partial deacetylation of chitin results in the production of chitosan, which is a polysaccharide 
comprising copolymers of glucosamine and N-acetylglucosamine. Chitosan is the ter4m 
applied to deacetylated chitins in various stages of deacetylation and depolymerization and it 
is therefore not easily defined in terms of its exact chemical composition. A clear 
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nomenclature with respect to the degrees of N-deacetylation between chitin and chitosan has 
not been defined, and as such chitosan is not one chemical entity but vadries in composition 
depending on the manufacturer. In essence, chitosan is chitin is chitin sufficiently 
deacetylated to form soluble amine salts. The degree of deacetylation necessary to obtain a 
soluble product must be greater than 80-85%. Chitosan is commercially available in several 
types and grades that vary in molecular weight by 10 000-1 000 000, and vary in degree of 
deacetylation and viscosity
 
STRUCTURAL FORMULA 
                           Fig 15: Structure of Chitosan 
 
FUNCTIONAL CATEGORY 
Coating agent; disintegrant; film-forming agent; mucoadhesive; tablet binder; viscosity 
increasing agent. 
APPLICATIONS 
Chitosan is used in cosmetics and is under investigation for use in a number of 
pharmaceutical formulations. The suitability and performance of chitosan as a component of 
pharmaceutical drug formulations for drug delivery applications has been investigated in 
numerous studies. These include controlled drug delivery applications, use as a component of 
mucosaadhesive dosage forms rapid release dosage forms,
 
improved peptide delivery colonic 
drug delivery systems,
 
and use for gene delivery. chitosan has been processed into several 
pharmaceutical forms including gels films, beads,
 
microspheres,
 
tablets and coating for 
liposomes.
 
Furthermore, chitosan may be processed into drug delivery systems using several 
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techniques including spray-drying, coatcervation, direct compression, and conventional 
granulation processes. 
DESCRIPTION 
Chitosan occurs as odorless, white or creamy-white powder or flakes. Fiber formation is quite 
common during precipitation and the chitosan may look „cottonlike 
PHARMACOEPIAL SPECIFICATIONS 
                         Table 9: Pharmacopeial Specifications for chitosan                                                                                          
 
 
TEST PhEur 
Identification 
Characters 
Appearance of solution 
Matter insoluble in water 
pH(1%w/v solution) 
Viscosity 
Degree of deacetylation 
Chlorides 
Heavy metals 
Loss of drying 
Sulfated ash 
+ 
+ 
+ 
<=0.5 
4.0-6.0 
+ 
+ 
+10.0-20.0% 
<=40ppm 
<=10% 
<=1.0% 
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TYPICAL PROPERTIES 
 Chitosan is cationic polyamine with a high charge density at pH<6.5, and so adheres to 
negatively charged surface and chelates metal ions. It is a linear polyelectrolyte with reactive 
hydroxyl and amino groups available in for chemical reaction and salt formation the 
properties of chitosan relate to its polyelectrolyte polymeric carbohydrate character. The 
presence of a number of amino groups allows chitosan to react chemically with anionic 
systems, which results in alteration of physiochemical characteristics of such combinations. 
The nitrogen in chitosan is mostly in the form of primary aliphatic amino groups. Chitosan 
therefore undergoes reaction typical of amines: for example N-acylation and Schiff 
reactions.(3) Almost all functional properties of chitosan depend on chain length, chain 
density , and chain charge distribution.(8) Numerous studies have demonstrated that the salt 
form, molecular weight, and degree of deacetylation as well as pH at which the chitosan is 
used all influence how this polymer is utilizes in pharmaceutical applications.(7) 
Acidity/alkalinity pH= 4.0-6.0(1 % w/v aqueous solution) 
Density 1.35-1.40 g/cm
3
 
Glass transition temperature 203
o
C 
Moisture content chitosan adsorbs moisture from the atmosphere, the amount of water 
adsorbed depending upon the initial moisture content and the temperature and relative 
humidity of the surrounding air.  
PARTICLE SIZE DISTRIBUTION 
Solubility sparingly soluble in water ; practically insoluble in ethanol(95%), other organic 
solvents, and neutral or alkali solutions at pH above approximately 6.5. chitosan dissolves 
readily in dilute and concentrated of most organic acids and to some extent in mineral 
inorganic acids(except phosphoric and sulfuric acids). Upon dissolution, amine groups of the 
polymer become protonated, resulting in a positively charged polysaccharide(RNH3) and 
chitosan salts (chloride,glutamate,etc.) that are soluble in water; the solubility is affected by 
the degree of deacetylation
.
 Solubility is also greatly influenced by the  addition of salts to the 
solution. The higher the ionic strength, the lower the solubility as a result of salting out effect, 
which leads to precipitation of chitosan solution. When chitosan is in solutions, the repulsions 
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between the deacetylated units and their neighboring glucosamine units cause it to exist in an 
extended conformation. Addition of an electrolyte reduces this effect and the molecule 
possesses a more random, coli-like conformation. 
 VISCOSITY (DYNAMIC)  
A wide range of viscosity types is commercially available. Owing to its high molecular 
weight and linear un-branched structure, chitosan is an excellent viscosity-enhancing agent in 
an acid environment. It acts as pseudo-plastic material, exhibiting a decrease in viscosity with 
increasing rate of sheer. The viscosity of chitosan solutions increases with increasing chitosan 
concentration, decreasing temperature, and increasing degree of deacetylation. 
      Table 10: Typical viscosity(dynamic) values for chitosan in different acids 
Acid 
 
 
1% acid concentration 5% acid concentration 
 
10% acid concentration 
 
Viscosity pH Viscosity pH viscosity Ph 
Acetic 260 4.1 260 3.3 260 2.9 
Adipic 190 4.1 - - - - 
Citric 35 3.0 195 2.3 215 2.0 
Formic 240 2.6 185 2.0 185 1.7 
Lactic 235 3.3 235 2.7 270 2.1 
Malic 180 3.3 205 2.3 220 2.1 
Malonic 195 2.5 - - - - 
Oxalic 12 1.8 100 1.1 100 0.8 
Tartaric 52 2.8 135 2.o 160 1.7 
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STABILITY AND STORAGE CONDITIONS
 
Chitosan powder is a stable material at room temperature, although it is a hygroscopic after 
drying. Chitosan should be stored in a tightly closed container in a cool, dry place. The PhEur 
6.5 specifies that chitosan should be stored at a temperature of 2-8
o
C 
INCOMPATABILITIES 
Chitosan is incompatible with strong oxidizing agents 
SAFTEY 
Chitosan is being investigated widely for use as an excipient in oral and other pharmaceutical 
formulations. It is also used in cosmetics. Chitosan is generally as a nontoxic and nonirritant 
material. It is biocompatible
 (41)
 with both healthy and infected skin. Chitosan has been shown 
to be biodegradable.  LD50(mouse, oral):>16g/Kg 
HANDLING PRECAUTIONS 
Observe normal precautions appropriate to the circumstances and quantity of material 
handled.  Chitosan is combustile; open flames should be avoided.  Chitosan is temperature 
sensitive and should not be heated above 200
o
C. Airborne chitosan dust may explode in the 
presence of a source of ignition, depending on its moisture content and particle size. Water, 
dry chemicals, carbon dioxide, sand, or, foam fire fighting media should be used. 
Chitosan may cause skin or eye irritation. It may be harmful if absorbed through the skin or if 
inhaled, and may be irritating to mucous membranes and the reparatory tract. Eye and skin 
protection and protective clothing are recommended; wash thoroughly after handling. 
Prolonged or repeated exposure (inhalation) should be avoided by handling in a well-
ventilated area and wearing a respirator. 
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D. SODIUM BICARBONATE  
NONPROPRIETARY NAMES 
• BP : Sodium bicarbonate 
• JP : Sodium bicarbonate 
• PhEur : Natrii hydrogenocarbonas 
• USP : Sodium bicarbonate 
SYNONYMS 
Baking soda; E500; Effer-Soda; monosodium carbonate; Sal de Vichy; sodium acid 
carbonate; sodium hydrogen carbonate. 
CHEMICAL NAME  
Carbonic acid monosodium salt  
EMPIRICAL FORMULA AND MOLECULAR WEIGHT 
 NaHCO3 84.01 
FUNCTIONAL CATEGORY 
Alkalizing agent; therapeutic agent. 
APPLICATIONS 
Sodium bicarbonate is generally used in pharmaceutical formulations as a source of carbon 
dioxide in effervescent tablets and granules. It is also widely used to produce or maintain an 
alkaline pH in a preparation. 
Tablets may also be prepared with Sodium bicarbonate alone since the acid of gastric fluid is 
sufficient to cause effervescence and disintegration. Sodium bicarbonate is also used in tablet 
formulations to buffer drug molecules that are weak acids, thereby increasing the rate of 
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tablet dissolution and reducing gastric irritation. The effects of tablet binders, such as 
polyethylene glycols, Microcrystalline cellulose, silicified Microcrystalline cellulose, 
pregelatinized starch, and povidone, on the physical and mechanical properties of Sodium 
bicarbonate tablets have also been investigated. Additionally, Sodium bicarbonate is used in 
solutions as a buffering agent for Erythromycin, Lidocaine,  local anesthetic solutions,  and 
total parenteral nutrition solutions.  In some parenteral formulations, e.g., in Niacin parenteral 
formulation, Sodium bicarbonate is used to produce a sodium salt of the active ingredient that 
has enhanced solubility. Sodium bicarbonate has also been used as a freeze-drying stabilizer 
and in toothpastes. Recently, Sodium bicarbonate has been used as a gas-forming agent in 
alginate raft system  and in floating, controlled-release oral dosage forms of Furosemide  and 
Cisapride.  Tablet formulations containing Sodium bicarbonate have been shown to increase 
the absorption of Paracetamol, and improve the stability of Levothyroxine. 
Sodium bicarbonate is used in food products as an alkali or as a leavening agent, e.g. baking 
soda. 
                                    Table 11: Uses of sodium bicarbonate 
Use Concentration (%) 
Buffer in tablets 10-40 
Effervescent tablets 25-50 
Isotonic injection/infusion 1.39 
 
Use Concentration (%) Buffer in tablets 10–40 Effervescent tablets 25–50 Isotonic 
injection/infusion 1.39 
Description: 
Sodium bicarbonate occurs as an odorless, white, crystalline powder with a saline, slightly 
alkaline taste. The crystal structure is monoclinic prisms. Grades with different particle sizes, 
from a fine powder to free-flowing uniform granules, are commercially available. 
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Typical Properties: 
Acidity/alkalinity:  pH = 8.3 for a freshly prepared 0.1 M aqueous solution at 25°C; alkalinity 
increases on standing, agitation, or heating. 
Density (bulk):  0.869 g/cm3 
Density (tapped):  1.369 g/cm3 
Density (true):  2.173 g/cm3 
Freezing point depression: 0.381°C (1% w/v solution) 
Melting point:  270°C (with decomposition) 
Moisture content: below 80% relative humidity, the moisture content is less than 1% w/w. 
Above 85% relative humidity, sodium bicarbonate rapidly absorbs excessive amounts of 
water and may start to decompose with loss of carbon dioxide. 
Osmolarity: a 1.39% w/v aqueous solution is isoosmotic with serum. 
 Refractive index: n20 D = 1.3344 (1% w/v aqueous solution 
Solubility: Solvent Solubility at 20°C unless otherwise stated Ethanol (95%) Practically 
insoluble Ether Practically insoluble 1 in 11 1 in 4 at 100°Ca 1 in 10 at 25°C Water 1 in 12 at 
18°C 
                               Table 12: Solubility of Sodium bi carbonate 
SOLVENT SOLUBILITY 
Ethanol(95%) Practically insoluble 
Ether Practically insoluble 
Water 1 in 4 at 100
0
C, 1 in 10 at 25
0
C, 1 in 12 at 
18
0
C 
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STABILITY AND STORAGE CONDITIONS 
When heated to about 50°C, Sodium bicarbonate begins to dissociate into carbon dioxide, 
sodium carbonate, and water; on heating to 250–300°C, for a short time, Sodium bicarbonate 
is completely converted into anhydrous sodium carbonate. The effects of relative humidity 
and temperature on the moisture sorption and stability of Sodium bicarbonate powder have 
been investigated. Sodium bicarbonate powder is stable below 76% relative humidity at 25°C 
and below 48% relative humidity at 40°C.At 54% relative humidity, the degree of pyrolytic 
decarboxylation of Sodium bicarbonate should not exceed 4.5% in order to avoid detrimental 
effects on stability. 
At ambient temperatures, aqueous solutions slowly decompose with partial conversion into 
the carbonate; the decomposition is accelerated by agitation or heat. Aqueous solutions of 
Sodium bicarbonate may be sterilized by filtration or autoclaving. To minimize 
decomposition of Sodium bicarbonate by decarboxylation on autoclaving, carbon dioxide is 
passed through the solution in its final container, which is then hermetically sealed and 
autoclaved. The sealed container should not be opened for at least 2 hours after it has 
returned to ambient temperature, to allow time for the complete reformation of the 
bicarbonate from the carbonate produced during the heating process. 
Sodium bicarbonate is stable in dry air but slowly decomposes in moist air and should 
therefore be stored in a well-closed container in a cool, dry place. 
INCOMPATIBILITIES 
Sodium bicarbonate reacts with acids, acidic salts, and many alkaloidal salts, with the 
evolution of carbon dioxide. Sodium bicarbonate can also intensify the darkening of 
salicylates. In powder mixtures, atmospheric moisture or water of crystallization from 
another ingredient is sufficient for Sodium bicarbonate to react with compounds such as boric 
acid or alum. In liquid mixtures containing bismuth subnitrate, Sodium bicarbonate reacts 
with the acid formed by hydrolysis of the bismuth salt. In solution, Sodium bicarbonate has 
been reported to be incompatible with many drug substances such as Ciprofloxacin, 
Amiodarone, Nicardipine, and Levofloxacin. 
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SAFTEY 
Sodium bicarbonate is used in a number of pharmaceutical formulations including injections 
and ophthalmic, otic, topical, and oral preparations. Sodium bicarbonate is metabolized to the 
sodium cation, which is eliminated from the body by renal excretion, and the bicarbonate 
anion, which becomes part of the body‟s bicarbonate store. Any carbon dioxide formed is 
eliminated via the lungs. Administration of excessive amounts of Sodium bicarbonate may 
thus disturb the body‟s electrolyte balance, leading to metabolic alkalosis. When used as an 
excipient, Sodium bicarbonate is generally regarded as an essentially nontoxic and nonirritant 
material. LD50 (mouse, oral) : 3.36 g/kg LD50 (rat, oral) : 4.22 g/kg Handling Precautions 
Observe normal precautions appropriate to the circumstances and quantity of material 
handled. Eye protection and gloves are recommended. 
REGULATORY STATUS 
GRAS listed. Accepted for use as a food additive in Europe. Included in the FDA Inactive 
Ingredients Guide (injections; ophthalmic preparations; oral capsules, solutions, and tablets). 
Included in parenteral (intravenous infusions and injections) and nonparenteral medicines 
(ear drops, eye lotions, oral capsules, chewable tablets, effervescent powders, effervescent 
tablets, granules, tablets, suppositories and suspensions) licensed in the UK. 
E.CITRIC ACID  
Nonproprietary Names 
BP: Citric Acid Monohydrate 
JP: Citric Acid Hydrate 
PhEur: Citric Acid Monohydrate 
USP: Citric Acid Monohydra 
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SYNONYMS 
Acidum citricum monohydricum; E330; 2-hydroxypropane-1,2,3- 
tricarboxylic acid monohydrate. 
CHEMICAL NAME 
2-Hydroxy-1,2,3-propanetricarboxylic acid  
4 Empirical Formula and Molecular Weight 
C6H8O7_H2O 210.14 
FUNCTIONAL CATEGORY 
Acidifying agent; antioxidant; buffering agent; chelating agent; 
flavor enhancer; preservative. 
 APPLICATIONS 
Citric acid (as either the monohydrate or anhydrous material) is widely used in 
pharmaceutical formulations and food products, primarily to adjust the pH of solutions. It has 
also been used experimentally to adjust the pH of tablet matrices in enteric-coated 
formulations for colon-specific drug delivery.(1) Citric acid monohydrate is used in the 
preparation of effervescent granules, while anhydrous citric acid is widely used in the 
preparation of effervescent tablets.(2–4) Citric acid has also been shown to improve the 
stability of spray-dried insulin powder in inhalation formulations. In food products, citric acid 
is used as a flavor enhancer for itstart, acidic taste. Citric acid monohydrate is used as a 
sequestering agent and antioxidant synergist; see Table I. It is also a componentof 
anticoagulant citrate solutions. Therapeutically, preparations containing citric acid have been 
used to dissolve renal calculi. 
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F.MAGNESIUM STEARATE 
SYNONYMS 
Dibasic magnesium stearate; magnesium distearate; magnesia stearate; magnesium 
octadecanoate; octadecanoic acid, magnesium salt; stearic acid, magnesium salt;  
STRUCTURE 
                               Fig 16: Structure of Magnesium stearate 
 
CHEMICAL NAME 
Octadecanoic acid magnesium salt. 
STRUCTURAL FORMULA 
[CH3 (CH2)16COO] 2Mg 
FUNCTIONAL CATEGORY 
Tablet and capsule lubricant. 
DESCRIPTION 
Magnesium stearate is a very fine, light white, precipitated or milled, impalpable powder of 
low bulk density, having a faint odor of stearic acid and a characteristic taste. The powder is 
greasy to the touch and readily adheres to the skin.  
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APPLICATIONS 
Magnesium stearate is widely used in cosmetics, foods, and pharmaceutical formulations. It 
is primarily used as a lubricant in capsule and tablet manufacture at concentrations between 
0.25% and 5.0% w/w. It is also used in barrier creams. 
STABILITY AND STORAGE CONDITIONS 
Magnesium stearate is stable and should be stored in a well-closed. container in a cool, dry 
place.  
INCOMPATIBILITIES 
Incompatible with strong acids, alkalis, and iron salts. Avoid mixing with strong oxidizing 
materials. Magnesium stearate cannot be used in products containing aspirin, some vitamins, 
and most alkaloid salts. 
G.CELLULOSE, MICROCRYSTALLINE (Avicel PH-101)  
NONPROPRIETARY NAMES 
BP : Microcrystalline cellulose  
JP : Microcrystalline cellulose  
PhEur : Cellulosum microcristallinum  
USPNF : Microcrystalline cellulose 
SYNONYMS 
Avicel PH; Celex; cellulose gel; Celphere; Ceolus KG; crystalline cellulose; E460; Emcocel; 
Ethispheres ; Fibrocel; Pharmacel; Tabulose; Vivapur. 
Chemical Name and CAS Registry Number: Cellulose [9004-34-6] 
Empirical Formula and Molecular Weight: (C6HO105)n =  36   000,where n =220. 
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FUNCTIONAL CATEGORY 
 Adsorbent; suspendin agent;   tablet and capsule diluent;   tablet disintegrant. 
STRUCTURAL FORMULA 
 
                                Fig 17: Structure of MCC 
APPLICATIONS 
Microcrystalline cellulose is widely used in pharmaceuticals, primarily as a binder/diluent in 
oral tablet and capsule formulations where it is used in both wet-granulation and 
directcompression processes.  In addition to its use as a binder/diluent, Microcrystalline 
cellulose also has some lubricant and disintegrant properties that make it useful in tableting. 
Microcrystalline cellulose is also used in cosmetics and food products. 
                Table 13: Uses of Microcrystalline cellulose. 
Si.No Use Concentration 
1 Adsorbent 20-90 
2 Antiadherent 5-20 
3 Capsule binder/diluents 20-90 
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4 Tablet disintegrent 5-15 
5 Tablet binder/diluent 20-90 
 
DESCRIPTION 
Microcrystalline cellulose is a purified, partially depolymerized cellulose that occurs as a 
white, odorless, tasteless, crystalline powder composed of porous particles. It is commercially 
available in different particle sizes and moisture grades that have different properties and 
applications. 
TYPICAL PROPERTIES 
Density (bulk):   0.32 g/cm for Avicel PH-101 
Density (tapped):  0.45 g/cm for Avicel PH-101; 
Density (true):   1 .512–1.668 g/cm 
Melting point:   C hars at 260–270°C. 
MOISTURE CONTENT 
 Typically less than 5% w/w. However, different grades may contain varying amounts of 
water. Microcrystalline cellulose is hygroscopic. 
PARTICLE SIZE DISTRIBUTION 
 Typical mean particle size is 20–200 µm. Different grades may have a different nominal 
mean particle size. 
SOLUBILITY 
 Slightly soluble in 5% w/v sodium hydroxide solution; practically insoluble in water, dilute 
acids, and most organic solvents. 
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STABILITY AND STORAGE CONDITIONS 
Microcrystalline cellulose is a stable though hygroscopic material. The bulk material should 
be stored in a well-closed container in a cool, dry place. 
INCOMPATIBILITIES 
Microcrystalline cellulose is incompatible with strong oxidizing agents. 
SAFTEY 
Microcrystalline cellulose is widely used in oral pharmaceutical formulations and food 
products and is generally regarded as a relatively nontoxic and nonirritant 
material.Microcrystalline cellulose is not absorbed systemically following oral 
administrationand thus has little toxic potential. Consumption of large quantities of cellulose 
may have a laxative effect, although this is unlikely to be a problem when cellulose is used as 
an excipient in pharmaceutical formulations. Deliberate abuse of formulations containing 
cellulose, either by inhalation or by injection, has resulted in the formation of cellulose 
granulomas. 
REGULATORY STATUS 
GRAS listed. Accepted for use as a food additive in Europe. Included in the FDA Inactive 
Ingredients Guide (inhalations; oral capsules, powders, suspensions, syrups, and tablets; 
topical and vaginal preparations). Included in non-parenteral medicines licensed in the UK. 
Included in the Canadian List of Acceptable Non-medicinal Ingredients. 
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MTHODOLOGY 
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                                      EXPEREMENTAL METHODS 
PREFORMULATION STUDIES 
Preformulation may be described as a stage of development during which the 
physicochemical and biopharmaceutical properties of a drug substance are characterized. It is 
important part of the drug development process. The information relating to drug 
development acquired during this phase is used for making critical decisions in subsequent 
stages of development. A wide variety of information must be generated to develop 
formulations rationally. Characterization of the drug is a very important step at the 
preformulation phase of product development followed by studying the properties of the 
excipients and their compatibility. 
The API was tested for the following properties: 
1.Physical characteristics 
 Solubility 
2. Drug excipients compatibility 
 
SOLUBILITY STUDY
44
 
The solubility study was used to identify the suitable solvent that possess good solubilizing 
capacity for Imatinib. Solubility of imatinib in various solvents was determined by adding 
excess of drug in each of selected solvents in each conical flask containing 20 ml and is 
shaken for 24 hours using Rotary shaking apparatus. Then the solubility of drug in each 
solvent is observed visually and by UV spectrophotometrically at maximum wave length of 
236 nm after relevant dilutions.
 
COMPATIBILITY STUDIES 
PHYSICAL COMPATIBILITY STUDIES
45 
Drug Excipient compatibility study by Stability studies 
 The drug-excipient compatibility studies were determined in 1:1 ratios under Humidity 
chamber at different temperature and humidity conditions for the period of four weeks. 
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            Table 14 : Drug and Excipients Compatibility by Stability Studies 
1. Drug and excipients ratios were accurately weighed and sifted  
2. Physical mixtures were blended in mortar with pestle to get uniformity 
3. The above mixtures were sieved through # 40 sieve. The blends were filled in glass 
vials with suitable stoppers 
4. Label the vials and charged at accelerated conditions. 
5. The drug-excipient blends were prepared and charged for accelerated conditions 
at40
o
C / 75%RH for a period of 1 month. The samples are analysed for related 
substances. 
6. FTIR studies were done to verify if there was any interaction between the pure drug 
and excipients employed. The various FTIR graphs of pure drug, excipients are 
mixed and the blend was formulated into IR pellet and scanned.  
CHMICAL COMPATIBILITY STUDIES
46
 
FTIR (Fourier transform infra-red spectroscopy) studies: 
Infra-red spectroscopy is widely used in pharmaceutical research. IR spectroscopy is 
routinely used for compound identification as a fingerprinting tool. IR spectroscopy also has 
its application in studies of drug – excipient interaction, contaminant analysis etc. IR 
spectrum with high quality is acquired with the FTIR method. Fourier transformation 
S. No. Drug and Excipients Ratio 
1 Imatinib  
2 Imatinib+ HPMC K15M 1:1 
3 Imatinib+ Carbopol 1:1 
4 Imatinib+ Chitosan 1:1 
6 Imatinib+ SBC 1:1 
7 Imatinib+ Citric acid 1:1 
8 Imatinib+ Magnesium sterate 1:1 
9 Imatinib+ MCC 
1:1 
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mathematical operation can resolve the signal captured by detector as a summation of all 
these signals and in connection with the contribution of each wavelength. Several sampling 
methods are available for IR spectrum acquisition, such as alkali halide pellet, mineral-oil 
mull, diffuse reflectance technique and attenuated total reflectance. Each has its advantages 
and disadvantages. 
IR spectrum with high quality is acquired with KBr pellet method. Compatibility study of 
drug with the excipients was determined by using FTIR. The sample powder of drugs, 
excipients and mixture of both were subjected to FTIR study. The mixture spectra were 
compared with that of the original spectra
 
STANDARD CURVE OF IMATINIB
47 
Preparation of 0.1N Hydrochloric acid: 
8.5 ml of concentrated hydrochloric acid was diluted with distilled water and the volume was 
made upto 1000ml with distilled water. 
Preparation of Imatinib Standard Stock Solution In 0.1N HCl: 
A Standard Solution of  Imatinib was prepared by dissolving accurately weighed 100 mg of 
Imatinib with little quantity of  0.1N HCl solution, in a 100 ml volumetric flask. The volume 
was made up to 100 ml with 0.1N HCl, to obtain a stock solution of 1000µg/ml. 
From the above solution several dilutions are made to obtain 50, 75, 100, 125, 150 mcg/ml 
solutions. The absorbencies of these drug solutions were estimated at λ max 236 nm. 
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FORMULATION DEVELOPMENT OF GASTRO-RETENTIVE TABLETS 
The active ingredient i.e. Imatinib and each single polymer (HPMC K15M, Carbopol, 
Chitosen) and also mixture of three polymers, filler (MCC), lubricant (Magnesium stearate), 
Gas forming ingredients (SBC, Citric acid mono-hydrate) were blended together by dry 
mixing in a laboratory mixer (polybag) for 10 mins. The mixture was compressed by using 
12mm standard flat round punch and die set at compression force 4-6 kg.  
 
 
Table 15: Formulation development of Imatinib Gastro-retentive tablets: 
 
Before going for the compression the drug and excipients blend is supposed to be evaluated 
for several pre-compression parameters which are given as follows. 
 
 
                              Quantity for each tablet(mg) 
SI.NO F1 F2 F3 F4 F5 F6 
API 100 100 100 100 100 100 
HPMC 
K15 
100 200 300 - - 100 
Carbopol - - - 300 - 100 
Chitosan - - - - 300 100 
SBC 30 30 30 30 30 30 
Citric acid 5 5 5 5 5 5 
Magnesium 
sterate 
10 10 10 10 10 10 
MCC 355 255 155 155 155 155 
Avg. Wt 600 600 600 600 600 600 
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PRE-COMPRESSION EVALUATION PARAMETERS 
Angle of repose
48
 
The angle of repose of powder blend was determined by the funnel method. The accurately 
weighed powder blends were taken in the funnel. The height of the funnel was maintained 
approximately 2-4 cm from the top of the powder pile in order to minimize the impact of 
falling powder on the tip of the cone. The powder blend was allowed to flow through the 
funnel freely on to the surface. The diameter of the powder cone was measured and angle of 
repose was calculated using the following equation.                                
                                                          
Where, h and r are the height and radius of the powder cone. 
              Table 16: Comparison between angle of repose and flow properties 
Angle of repose ( θ ) Flow 
< 25 Excellent 
25 – 30 Good 
30 – 40 Moderate (addition of 0.2% glidant required) 
> 40 Poor 
 
Bulk Density
49 
About 20gms of material was passed through a sieve #40 to break up agglomerates and 
introduced into a dry 50 ml cylinder. Without compacting the powder carefully leveled and 
the un-settled apparent volume, Vo, was recorded. The bulk density was calculated in grams 
per mL, using the following formula 
                                                  Bulk density = M/V0 
Where, M = total mass of the material.  
Tapped Density  
After carrying out the procedure as given in the measurement of bulk density the cylinder 
containing the sample was tapped using a mechanical tapped density tester. The cylinder was 
tapped until no change in volume and then tapped volume Vf was measured to the nearest 
graduated unit. The tapped density was calculated, in grams per mL, using the formula: 
 
                                                  Tapped density = M/ Vf 
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Hausner’s Ratio 
It indicates the flow properties of the granules and is measured by the ratio of tapped density 
to the bulk density. 
 
                  
               
            
 
                         Table 17: Scale of Flowability according to Hausner’s ratio 
Hausner’s ratio Flow character 
1.0-1.11 Excellent 
1.12-1.18 Good 
1.19-1.25 Fair 
1.26-1.34 Passable 
1.35-1.45 Poor 
1.46-1.59 Very poor 
> 1.60 Very, very poor 
 
Compressibility index (Carr’s Index): CI 
Compressibility index is an important measure that can be obtained from the bulk and tapped 
densities. In theory, the less compressible a material the more flowable it is. A material having 
values of less than 20% has good flow property
 
   
(                           )
             
     
                   Table 18: Scale of Flowability according to Compressibility index
 
 
 
 
 
 
 
 
 
 
 
 
% Comp. Index Properties 
<12 Free flowing 
12-16 Good 
18-21 Fair 
23-35 Poor 
33-38 Very poor 
>40 Extremely poor 
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Post compression evaluation parameters 
The tablets were evaluated for in process and finished product quality control tests i.e. 
appearance, dimensions (diameter and thickness), weight variation, hardness, friability, assay, 
and drug content.  
Weight variation
50
  
The weight of the tablet being made was routinely determined to ensure that a tablet contains 
the proper amount of drug. The USP weight variation test is done by weighing 20 tablets 
individually, calculating the average weight and comparing the individual weights to the 
average. The tablets met the USP specification that not more than 2 tablets are outside the 
percentage limits and no tablet differs by more than 2 times the percentage limit. USP official 
limits of percentage deviation of tablet are presented in the table. 
                               Table 19: Weight variation limits 
Maximum % of weight 
difference allowed 
Average weight of tablet (mg) 
USP IP 
10 <130 <80 
7.5 130- 324 80 – 250 
5    >324 >250 
 
 Tablet hardness
51 
The resistance of tablets to shipping or breakage under conditions of storage, transportation 
and handling before usage depends on its hardness. The hardness of each batch of tablet was 
checked by using Monsanto hardness tester. The hardness was measured in terms of kg/cm
2
. 
3 tablets were chosen randomly and tested for hardness.  The average hardness of 3 
determinations was recorded. 
Friability 
Friability generally refers to loss in weight of tablets in the containers due to removal of fines 
from the tablet surface. Friability generally reflects poor cohesion of tablet ingredients.  
Method 
10 tablets were weighed and the initial weight of these tablets was recorded and placed in 
Roche friabilator and rotated at the speed of 25 rpm for 100 revolutions.  Then tablets were 
removed from the friabilator, dusted off the fines and again weighed and the weight was 
recorded. 
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(     )
  
     
Where:w1= weight of the tablet before test.                                                                                    
.           w2 = weight of the tablet after test 
 
Content Uniformity
52
 
The tablets were tested for their drug content uniformity. At random 10 tablets were weighed 
and powdered. The powder equivalent to 100 mg of drug was weighed accurately and 
dissolved in 100ml of 0.1N HCl solution. The solution was shaken thoroughly. The un-
dissolved matter was removed by filtration through Whatman No.1 filter paper. Then transfer 
1mL of the above solution into 100mL volumetric flask and make up the volume with 0.1N 
HCl solution. The absorbance of the diluted solutions was measured at 236nm. By using UV 
spectrophotometer taking 0.1N HCl as blank 
In-Vitro Buoyancy studies
53
 
In vitro buoyancy was determined by floating lag time. The tablets were placed in a 100 mL 
beaker containing 0.1N HCL. The time required for the tablet to rise to the surface and to 
float was determined as floating lag time. The duration of time for which the dosage 
constantly remained on the surface of medium was determined as the total floating time.  
Swelling studies 
The extent of swelling was measured in terms of % of weight gained by the tablet. One tablet 
from each formulation was introduced into Basket type dissolution apparatus containing 900 
ml 0.1N HCl (37
0
C) at 50 RPM, the tablets were removed at different time intervals and the 
weight of the swollen tablet is noted. 
Finally the swelling index of the tablet was calculated by using the formula below 
                                        
             Where, Mt – weight of tablets at time„t‟; 
                          M0 –initial weight of tablets 
 
 
 
 
 
 
Swelling index (%) = 
Mt – M0 
M0 
X 100 
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 In-Vitro Dissolution studies
54 
The in vitro drug release study was performed for all the tablets using USP type II dissolution 
apparatus under the following conditions. 
 
 
Dissolution test parameters: 
Medium 900 mL of 0.1N HCl 
Temperature 37ºC±0.5ºC 
RPM 50 
Sampling  
Volume 
5 ml 
Sampling time 1, 4, 8, 16, 20 hours  
Preparation 0.1 N HCl:  
Take 8.5 ml of concentrated hydrochloric acid in a 1000 ml volumetric flask and make up the 
volume.  
Procedure 
Tablet was introduced into dissolution test apparatus and the apparatus was set at 50rpm. 5 ml 
of sample was withdrawn at the predetermined time intervals. Samples were analyzed by UV 
spectrophotometer at 236nm using 0.1N HCl solution as blank. 
Stability studies
55 
Stability of a drug has been defined as the ability of a particular formulation, in a specific 
container, to remain within its physical, chemical, therapeutic and toxicological 
specifications. Stability studies were conducted for the optimized gastroretentive formulation 
of Imatinib. The stabilitystudy  was performed as per following. 
Preliminary stability of the optimized batch 
The optimized batch (F4) was charged for accelerated stability studies as per ICH guidelines. 
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RESULTS AND DISCUSION 
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                                                         Results 
In the present work tablet dosage form containing Imatinib were prepared by using direct 
compression method. The prepared dosage forms were evaluated by different methods which 
are as follows. 
 
SOLUBILITY STUDIES 
The solubility of Imatinib is evaluated in different solvents. 
 
          Fig 18: Comparison of solubility profile of Imatinib in different solvents 
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COMPATIBILITY STUDIES 
PHYSICAL COMPATIBILITY 
 
Table 20: Results of Excipients Compatibility by Stability Studies 
S. No. Drug and Excipients 
Initial Physical 
Description 
40C / 75% RH (Closed) 
1st 
Week 
2nd 
Week 
4th 
Week 
1 Imatinib White  powder NCC NCC NCC 
2 Imatinib+ HPMC K15M Off-white powder NCC NCC NCC 
3 Imatinib+ Carbopol Off-white powder NCC NCC NCC 
4 Imatinib+ Chitosan Off white powder NCC NCC NCC 
6 Imatinib+ SBC white powder NCC NCC NCC 
7 Imatinib+ Citric acid Off-white powder NCC NCC NCC 
8 
Imatinib+ Magnesium 
sterate 
Off-white powder NCC NCC NCC 
9 Imatinib+ MCC 
Off-white powder 
 
NCC NCC NCC 
NCC indicates that there is no interaction between drug and excipients at 40C/75% RH. 
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CHEMICAL COMPATIBILITY 
Compatability study of active pharmaceutical ingredient and excipients: 
The drug and excipient mixtures are evaluated for chemical compatibility by means of FTIR 
and the results are given in the following figures  
                                             Fig 19: Spectra of Pure Drug 
 
                                 Fig 20: Spectra of Pure Drug and HPMC K15M 
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                           Fig 21: Spectra of Pure Drug and Carbopol 
 
 
                              Fig 22: Spectra of Pure Drug and Chitosan 
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                     Fig 23: Spectra of Pure Drug and Citric Acid 
 
                       Fig24: Spectra of Pure Drug and MCC 
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                 Fig 25: Spectra of Pure drug and Sodium Bi Carbonate 
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Standard curve of  Imatinib 
Table 21: Absorbance of Imatinib with different concentrations at 236nm 
 
 
 
Fig 26: Calibration curve of Imatinib in 0.1N HCl solution, at 236 nm. 
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Calibration Curve of IMATINIB 
Series1
Linear (Series1)
SI.NO Concentration(mcg/ml) Absorbance 
1 0 0 
2 50 0.1722 
3 75 0.2583 
4 100 0.3513 
5 125 0.4313 
6 150 0.5456 
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PRE-COMPRESSION RESULTS 
Bulk density: 
                                      Table 22: Data for bulk density 
SI.NO FORMULATION CODE BULK DENSITY (gm/ml) 
 
1 F-1 0.6666±0.005 
2 F-2 0.6486±0.003 
3 F-3 0.6857±0.006 
4 F-4 0.6315±0.002 
5 F-5 0.6857±0.004 
6 F-6 0.6153±0.003 
 
 
Fig 27: COMPARISON OF BULK DENSITY OF THE FORMULATIONS F1-F6 
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Tapped Density: 
The tapped density results are been found to be as following 
                              Table 23: Data for tapped density 
SI.NO FORMULATION CODE TAPPED 
DENSITY(gm/ml) 
1 F1 0.7058±0.008 
2 F2 0.6666±0.004 
3 F3 0.7058±0.009 
4 F4 0.6666±0.003 
5 F5 0.7272±0.004 
6 F6 0.6606±0.006 
 
             Fig 28: Comparison of Tapped density of formulations F1-F6 
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Hausner’s ratio and Compressability index: 
Table 24: Data for Hausner’s ratio and Compressability index 
 
 
 
 
 
 
 
 
 
 
 
 
Formulation code Hausner’s Ratio Compressibility Index (%) 
F-1 1.0585±0.005 5.5319±0.381 
F-2 1.026±0.003 2.6126±0.214 
F-3 1.029±0.003 2.8478±0.271 
F-4 1.0555±0.002 7.764±0.179 
F-5 1.0605±0.006 5.7608±0.004 
F-6 1.0829±0.004 7.6957±0.285 
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          Fig 29: Comparison of Hausner’s ratio of formulations F1-F6 
 
          Fig 30: Comparison of Compressibility index of formulations F1-F6 
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ANGLE OF REPOSE: 
                                    Table 25: Data for Angle of repose 
SI.NO FORMULATION ANGLE OF REPOSE 
1 F1 21
0
.69' ± 0.325 
2 F2 24
0
.22' ± 0.826 
3 F3 29
0
.64' ± 0.418 
4 F4 25
0
.80' ± 0.488 
5 F5 23
0
.39' ± 0.075 
6 F6 26
0
.54' ± 0.870 
 
                             Fig 31: Comparison of angle of repose 
 
Therefore from the above results we can conclude that the tablets blend has good flow 
properties. 
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POST COMPRESSION EVALUATION: 
Weight variation: 
                                     Table 26: Weight Variation data 
SI.NO FORMULATION CODE WEIGHT VARIATION 
1 F1 608.25±1.8477 
2 F2 603.95±0.8322 
3 F3 602.65±0.5925 
4 F4 601.65±0.368 
5 F5 602.15±0.4807 
6 F6 602.8±0.626 
 
                           Fig 32: Comparison of Weight Variation 
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TABLET HARDNESS: 
                                         Table 27: Hardness data 
 
SI.NO FORMULATION CODE HARDNESS(Kg/cm
2
) 
1 F1 6.325 ±0.1027 
2 F2 6.2 ±0.0632 
3 F3 6.25 ±0.079 
4 F4 6.175 ±0.0553 
5 F5 6.25 ±0.079 
6 F6 6.15 ±0.0474 
 
                                       Fig 33: Comparison of hardness 
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FRIABILITY 
                                              Table 28: Friability data 
SI.NO FORMULATION CODE FRIABILITY (%) 
1 F1 0.81 
2 F2 0.96 
3 F3 0.80 
4 F4 0.48 
5 F5 0.80 
6 F6 0.48 
 
 
 
                                         Fig 34: Comparison of friability 
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DRUG CONTENT UNIFORMITY: 
                                       Table 29: Drug content data 
SI.NO FORMULATION CODE DRUG CONTENT (%) 
1 F1 98.25 
2 F2 99.0 
3 F3 98.0 
4 F4 99.15 
5 F5 98.45 
6 F6 98.1 
 
                                     Fig 35: Comparison of drug content 
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In-Vitro Buoyancy studies 
Floating Lag time 
                                   Table 30: Data of Floating lag time 
SI.NO FORMULATION CODE FLOATING LAG TIME 
(SEC) 
TOTAL FLOATING 
TIME 
1 F1 - Remains at the bottom 
2 F2 192 14 hours 
3 F3 189 16 hours 
4 F4 257 18 hours 
5 F5 221 18 hours 
6 F6 124 18 hours 
 
                                Fig 36: Comparison of Floating lag time  
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Swelling index: 
                                        Table 31: Data for swelling index 
SI.NO. TIME                 Swelling Index(%) for different formulations   
F1 F2 F3 F4 F5 F6 
1 0 0 0 0 0 0 0 
2 1 75 91.6 101.6 120 108 130 
3 4 108.3 126.6 148.3 201 175 160 
4 8 136 165 186 226 193 215 
5 16 118.3 151 175 198 163 195 
 
                                   Fig 37: Comparison of swelling index 
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In-Vitro Dissolution studies: 
                 Table 32: In-Vitro Dissolution Study data for formulation F1 
SI.NO TIME(hrs) % Cumulative drug release 
1 1 43.6±0.285 
2 4 61.5±0.122 
3 8 84.9±0.285 
4 16 94.2±0.326 
5 20 93.4±0.163 
 
 
                                    Fig 38: Dissolution profile of F1 
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Table 33: In-Vitro Dissolution data for formulation F2 
SI.NO TIME (hrs) % Cumulative drug release 
 
1 1 44.1±0.122 
2 4 66.6±1.428 
3 8 80.2±0.285 
4 16 88.1±0.367 
5 20 95.8±0.040 
 
 
 
                                    Fig 39: Dissolution profile of F2 
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Table 34: In-Vitro Dissolution data for formulation of F3 
SI.NO TIME(hrs) % Cumulative drug release 
 
1 1 38.9±1.714 
2 4 57.3±0.816 
3 8 85.5±3.347 
4 16 91.0±0.326 
5 20 95.9±0.449 
 
 
 
 
                                  Fig 40: Dissolution profile of F3 
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Table 35: In-Vitro Dissolution data for formulation of F4 
SI.NO TIME (hrs) % Cumulative drug release 
 
1 1 36.3±0.898 
2 4 57.2±0.367 
3 8 77.4±0.653 
4 16 84.4±0.408 
5 20 94.3±1.020 
 
 
 
                                  Fig 41: Dissolution profile of F4 
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Table 36: In-Vitro Dissolution data for formulation of F5 
SI.NO TIME (hrs) % Cumulative drug release 
 
1 1 39.9±0.571 
2 4 62.6±0.612 
3 8 88.2±2.204 
4 16 94.4±0.081 
5 20 94.3±0.816 
 
 
 
                                 Fig 42: Dissolution profile of F5 
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Table 37: In-Vitro Dissolution data for formulation of F6 
SI.NO TIME(hrs) % Cumulative drug release 
 
1 1 40±0.530 
2 4 61.9±0.163 
3 8 93.3±0.244 
4 16 93.9±0.081 
5 20 99.1±0.040 
 
 
                            Fig 43: Dissolution profile of F6 
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Fig 44: Comparision of In-Vitro Dissolution profiles of formulations F1-F6 
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PHARMACOKINETIC MODELING 
                              Table 38: Pharmacokinetic modeling of F1  
S.NO TIME(hrs) CPR Log 
CPR 
Log T SQRT % Drug 
retained 
Log % 
Drug 
retained 
1 1 43.6 1.6394 0 1 56.4 1.7512 
2 4 61.5 1.7888 0.6020 2 38.5 1.5854 
3 8 84.9 1.9289 0.9030 2.82 15.1 1.1789 
4 16 94.2 1.9740 1.2041 4 5.8 0.7634 
5 20 93.4 1.9703 1.3010 4.4721 6.6 0.8195 
 
                        Fig 45: Pharmacokinetic modeling of F1 
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                               Table 39: Pharmacokinetic modeling of F2 
S.NO TIME(hrs) CPR Log 
CPR 
Log T SQRT % DRUG 
RETAINED 
Log % 
DRUG 
RETAINED 
1 1 44.1 1.6444 0 1 55.9 1.7474 
2 4 66.6 1.8234 0.6020 2 33.4 1.5237 
3 8 80.2 1.9041 0.9030 2.8284 19.8 1.2966 
4 16 88.1 1.9449 1.2041 4 11.9 1.0755 
5 20 95.8 1.9813 1.3010 4.4721 4.2 0.6232 
 
                         Fig 46: Pharmacokinetic modeling of F2 
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                          Table 40: Pharmacokinetic modeling of F3 
S.NO TIME(hrs) CPR Log 
CPR 
Log T SQRT % Drug 
retained 
Log % 
Drug 
retained 
1 1 38.9 1.5899 0 1 61.1 1.786 
2 4 57.3 1.7581 0.6020 2 42.7 1.630 
3 8 85.5 1.9319 0.9030 2.82 14.5 1.1613 
4 16 91 1.959 1.2041 4 9 0.9542 
5 20 95.9 1.9818 1.3010 4.4721 4.1 0.6127 
 
                    Fig 47: Pharmacokinetic modeling of F3 
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                                  Table 41: Pharmacokinetic modeling of F4 
S.NO TIME(hrs) CPR Log 
CPR 
Log T SQRT % Drug 
retained 
Log % 
Drug 
retained 
1 1 36.3 1.5599 0 1 63.7 1.8041 
2 4 57.2 1.7573 0.6020 2 42.8 1.6314 
3 8 77.4 1.8887 0.9030 2.82 22.6 1.3541 
4 16 84.4 1.9263 1.2041 4 15.6 1.1931 
5 20 92.3 1.9652 1.3010 4.4721 7.7 0.8864 
 
                        Fig 48: Pharmacokinetic modeling of F4 
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                              Table 42: Pharmacokinetic modeling of F5 
S.NO TIME(hrs) CPR Log 
CPR 
Log T SQRT % Drug 
retained 
Log % 
Drug 
retained 
1 1 39.9 1.6009 0 1 60.1 1.7788 
2 4 62.6 1.7965 0.6020 2 37.4 1.5728 
3 8 88.2 1.9454 0.9030 2.82 11.8 1.0718 
4 16 94.4 1.9749 1.2041 4 5.6 0.7481 
5 20 94.3 1.9745 1.3010 4.4721 5.7 0.7558 
 
                       Fig 49: Pharmacokinetic modeling of F5 
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                          Table 43: Pharmacokinetic modeling of F6 
S.NO TIME(hrs) CPR Log 
CPR 
Log T SQRT % Drug 
retained 
Log % 
Drug 
retained 
1 1 40.0 1.6020 0 1 60 1.7781 
2 4 61.9 1.7916 0.6020 2 38.1 1.5809 
3 8 93.3 1.9698 0.9030 2.82 6.7 0.8260 
4 16 93.9 1.9726 1.2041 4 6.1 0.7853 
5 20 99.1 1.9960 1.3010 4.4721 0.9 -0.0457 
 
                         Fig 50: Pharmacokinetic modeling of F6 
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TABLE 44: SUMMARY OF PHRMACO KINETIC MODELING OF ALL THE 
FORMULATIONS. 
S.NO FORMULATION 
CODE 
ZERO ORDER FIRST 
ORDER 
HIGUCHI KORSMEYER-
PEPPAS 
MODEL 
R
2 
SLOP
E 
R
2 
SLO
PE 
R
2 
SLOP
E 
R
2 
N 
1 F1 0.8177 2.5059 0.817
7 
2.505
9 
0.9193 14.961 0.9681 0.2708 
2 F2 0.8594 2.3546 0.952
4 
0.052
7 
0.9517 13.953 0.9854 0.253 
3 F3 0.8228 2.7797 0.953
2 
-0.05 
88 
0.9176 16.529 0.9627 0.3123 
4 F4 0.8602 2.6255 0.958
6 
-0.04 
41 
0.9489 15.527 0.982 0.3109 
5 F5 0.7679 2.6253 0.901 0.055
9 
0.8867 15.885 0.9556 0.3011 
6 F6 0.7536 2.7085 0.884
5 
0.085
3 
0.8674 16.798 0.9425 0.3123 
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       Table 45: In-Vitro Dissolution of Formulation F4 after Stability studies 
Invitro dissolution after 30 days at 40°c / 
75%RH 
Invitro dissolution after 90 days at 40°c / 
75%RH 
Dissolution   
medium 
Time in 
hours 
Cumulative 
percentage 
drug release 
Dissolution   
medium 
Time in 
hours 
Cumulative 
percentage 
drug release 
(%) 
0.1N HCl 
Solution 
 
1 
 
38.4±0.024 
0.1N HCl  
Solution 
 
1 
 
34.1±0.002 
4 56.3±0.153 4 57.8±0.18 
8 78.2±0.085 8 77±0.125 
16 84.9±0.219 16 83.6±0.225 
20 92.3±0.135 20 92.1±0.216 
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Fig 51: Comparison of dissolution data of the optimized formulation F4 after 30 days 
and 90 days of stability studies with that of the Initial release. 
 
 
 
                Table 46: Drug Content of ideal formulation after stability studies 
                  
SI.NO Days Drug content 
1 30 99.11 
2 90 98.49 
 
                Table 47: Data for Swelling index after 90 days of stability studies 
SI.NO TIME SWELLING INDEX (%) 
  30days 90 days 
1 1 109 115 
2 4 194 189 
3 8 220 218 
4 16 185 175 
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                                                    DISCUSSION 
In the present study the gastro-retentive dosage form of Imatinib was formulated and 
evaluated successfully. 
In the preformulation studies the API was tested for its Solubility and Compatibility with 
excipients. 
Solubility studies showed that the drug was highly soluble in DMSO, 0.1N HCl and in Water. 
Compatibility studies are done for both physical and chemical compatibilities. Physical 
Compatibility studies showed that there is no characteristic change in the drug and excipient 
mixture after a period of 4 weeks. 
Chemical compatibility studies were done by using FTIR spectroscopy and found that the 
drug and excipients do not have any chemical interactions. 
Pre compression evaluation of the blend was done by means of Angle of repose, Bulk 
density, Tapped density, Hausner‟s ratio and Compressibility index. 
The Hausner‟s ratios of all the formulations are in the range of 1.026 ± 0.003 to1.0829 ± 
0.004 meanwhile the Compressibility index values are in the range of 2.8478 ± 0.271 to 
7.764 ± 0.179 proving the fact that the tablet blend has good flow properties.  
Angle of repose values were also conforming the same by showing the results in the range of 
21
0
.69' to 29
0
.64'. Hence we can conclude that the tablet blend has got good flow properties. 
Immediately after compression, the tablets were evaluated by several tests such as Weight 
variation, Hardness, Friability, Drug content uniformity, In-Vitro buoyancy and In-Vitro 
dissolution studies.  
The weights of all the formulations are in the range of 601 to 608 showing that all the 
formulations are within the pharmacopeial limits of weight variation.  
Friability results of all the formulations were found to be less than 1% and all the 
formulations passed the test. 
During the in-vitro buoyancy studies the tablets were evaluated for their floating lag time and 
total floating time and the formulation F1 failed to float during the study, therefore the 
polymer ratio was increased from the next formulations. All the other formulations  showed 
good floating lag time. When comparing all the formulations, the formulations F4, F5, F6 has 
total floating time of 18 hours with acceptable floating lag time.  
The Swelling index studies showed that the swelling of a tablet increases with increase in the 
polymer ratio and the formulation F3, F4  showed higher swelling index than the others. 
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Drug content uniformity studies were done to find out the amount of API present in the 
prepared formulations. All the formulations had uniform drug content as per pharmacopeial 
limits. 
The in-vitro dissolution studies were carried out for the time periods of 1,4,8,16,20 hours. It 
was found that all the formulations  showed good release in the range of 93.4 to 99.1%, 
whereas formulation F4 showed 94.3% drug release in a controlled manner over a period of 
20 hours, so that was chosen as the best formulation.  
Pharmacokinetic modeling was done for all the formulations and found that the best 
formulation is obeying First order kinetics and fickian diffusion for drug release. 
Finally the ideal formulation was subjected to stability studies for a period of 90 days and the  
drug release, drug content and swelling index were compared with that of the initial data and 
found that there was no significant change in the values indicating a stable formulation. 
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                              SUMMARY AND CONCLUSION 
A total of 6 trials were formulated by direct compression method by using different polymers 
to find out the ideal formulation which can release the drug in a controlled manner over a 
period of 20 hours. Based on pre compression, post compression parameters and the drug 
release profile F4 was selected as the ideal formulation. 
When the drug release was fitted in pharmacokinetic modeling the ideal formulation F4 was 
releasing in first order process with fickian diffusion. 
The ideal formulation F4 was subjected to stability studies and found that there is no 
deviation of drug release to that of initial release. Therefore we conclude that a stable & 
effective dosage form giving the required drug release in a controlled manner was 
successfully formulated. 
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